
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            A competing risk analysis of predictors of time to lost to follow-up among adults with TB/HIV coinfection in Bahir Dar - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE53446C8AF4182305446C002818A6D2.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="scirep">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365281/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Scientific Reports">
<meta name="citation_title" content="A competing risk analysis of predictors of time to lost to follow-up among adults with TB/HIV coinfection in Bahir Dar">
<meta name="citation_author" content="Robel Demelash">
<meta name="citation_author_institution" content="Department of Family Health, Hossana College of Health Sciences, Hossana, Ethiopia">
<meta name="citation_author" content="Getachew Hailu">
<meta name="citation_author_institution" content="Department of Epidemiology and Biostatistics, School of Public Health, Bahir Dar University, Bahir Dar, Ethiopia">
<meta name="citation_author" content="Taye Abuhay">
<meta name="citation_author_institution" content="Department of Epidemiology and Biostatistics, School of Public Health, Bahir Dar University, Bahir Dar, Ethiopia">
<meta name="citation_author" content="Zemenu Addis">
<meta name="citation_author_institution" content="Department of Nursing, Hossana College of Health Sciences, Hossana, Ethiopia">
<meta name="citation_author" content="Ayenew Tega">
<meta name="citation_author_institution" content="Department of Midwifery, Hossanna College of Health Sciences, Hossanna, Ethiopia">
<meta name="citation_author" content="Degarege Nibret">
<meta name="citation_author_institution" content="Department of Family Health, Hossana College of Health Sciences, Hossana, Ethiopia">
<meta name="citation_author" content="Yitagesu Habtu">
<meta name="citation_author_institution" content="Department of Family Health, Hossana College of Health Sciences, Hossana, Ethiopia">
<meta name="citation_publication_date" content="2025 Aug 19">
<meta name="citation_volume" content="15">
<meta name="citation_firstpage" content="30362">
<meta name="citation_doi" content="10.1038/s41598-025-15985-8">
<meta name="citation_pmid" content="40830417">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365281/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365281/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365281/pdf/41598_2025_Article_15985.pdf">
<meta name="description" content="Lost to follow-up (LTFU), defined as interrupting anti-TB treatment for ≥ 8 consecutive weeks or missing anti-retroviral therapy (ART) appointments for &gt; 90 days, is a barrier to TB/HIV coinfection management. Poor treatment adherence, a driver of ...">
<meta name="og:title" content="A competing risk analysis of predictors of time to lost to follow-up among adults with TB/HIV coinfection in Bahir Dar">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Lost to follow-up (LTFU), defined as interrupting anti-TB treatment for ≥ 8 consecutive weeks or missing anti-retroviral therapy (ART) appointments for &gt; 90 days, is a barrier to TB/HIV coinfection management. Poor treatment adherence, a driver of ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365281/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12365281">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1038/s41598-025-15985-8"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/41598_2025_Article_15985.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365281%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12365281/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12365281/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365281/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-scirep.jpg" alt="Scientific Reports logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Scientific Reports" title="Link to Scientific Reports" shape="default" href="http://www.nature.com/srep" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Sci Rep</button></div>. 2025 Aug 19;15:30362. doi: <a href="https://doi.org/10.1038/s41598-025-15985-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1038/s41598-025-15985-8</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Sci%20Rep%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sci%20Rep%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Sci%20Rep%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Sci%20Rep%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>A competing risk analysis of predictors of time to lost to follow-up among adults with TB/HIV coinfection in Bahir Dar</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Demelash%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Robel Demelash</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Robel Demelash</span></h3>
<div class="p">
<sup>1</sup>Department of Family Health, Hossana College of Health Sciences, Hossana, Ethiopia </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Demelash%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Robel Demelash</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hailu%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Getachew Hailu</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Getachew Hailu</span></h3>
<div class="p">
<sup>2</sup>Department of Epidemiology and Biostatistics, School of Public Health, Bahir Dar University, Bahir Dar, Ethiopia </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hailu%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Getachew Hailu</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abuhay%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Taye Abuhay</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Taye Abuhay</span></h3>
<div class="p">
<sup>2</sup>Department of Epidemiology and Biostatistics, School of Public Health, Bahir Dar University, Bahir Dar, Ethiopia </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Abuhay%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Taye Abuhay</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Addis%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Zemenu Addis</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Zemenu Addis</span></h3>
<div class="p">
<sup>3</sup>Department of Nursing, Hossana College of Health Sciences, Hossana, Ethiopia </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Addis%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zemenu Addis</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tega%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Ayenew Tega</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Ayenew Tega</span></h3>
<div class="p">
<sup>4</sup>Department of Midwifery, Hossanna College of Health Sciences, Hossanna, Ethiopia </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tega%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ayenew Tega</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nibret%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Degarege Nibret</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Degarege Nibret</span></h3>
<div class="p">
<sup>1</sup>Department of Family Health, Hossana College of Health Sciences, Hossana, Ethiopia </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nibret%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Degarege Nibret</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Habtu%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Yitagesu Habtu</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Yitagesu Habtu</span></h3>
<div class="p">
<sup>1</sup>Department of Family Health, Hossana College of Health Sciences, Hossana, Ethiopia </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Habtu%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yitagesu Habtu</span></a>
</div>
</div>
<sup>1</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Family Health, Hossana College of Health Sciences, Hossana, Ethiopia </div>
<div id="Aff2">
<sup>2</sup>Department of Epidemiology and Biostatistics, School of Public Health, Bahir Dar University, Bahir Dar, Ethiopia </div>
<div id="Aff3">
<sup>3</sup>Department of Nursing, Hossana College of Health Sciences, Hossana, Ethiopia </div>
<div id="Aff4">
<sup>4</sup>Department of Midwifery, Hossanna College of Health Sciences, Hossanna, Ethiopia </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Nov 18; Accepted 2025 Aug 12; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12365281  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40830417/" class="usa-link">40830417</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Lost to follow-up (LTFU), defined as interrupting anti-TB treatment for ≥ 8 consecutive weeks or missing anti-retroviral therapy (ART) appointments for &gt; 90 days, is a barrier to TB/HIV coinfection management. Poor treatment adherence, a driver of multidrug resistance in TB/HIV, poses critical challenges to case management. Overestimating effect sizes when considering mutually exclusive events, like LTFU from ART and anti-TB treatment, can occur if sources of error are not properly accounted for in competing events. However, studies estimating the effect sizes of predictors of time to LTFU using competing risk analysis are scarce. Hence, this study aimed to investigate the predictors of time to LTFU among adults with TB/HIV coinfection. We conducted a multicenter facility-based retrospective follow-up study. We randomly selected 471 TB/HIV coinfected adults. Data were extracted using standardised checklists. The LTFUs from ART and anti-TB treatment were events of interest and competing events, respectively, and others were censored. The data were entered into Epi data and then exported to Stata and Rstudio. Statistical differences were tested by Gray’s test, and the cumulative incidence of each event was estimated by a cumulative incidence function. Bivariable and multivariable competing risk regression models were fitted, and variables with p values &lt; 0.05 were considered significant predictors. Incidence rates of LTFU for ART and TB treatment were 3.90 and 19.17 per 1000 person-months of observation (PMOs), respectively. The predictors of ART LTFU included rural residence (adjusted subdistribution hazard ratio (SDHR): 3.39), WHO stage IV (SDHR: 2.88), haemoglobin &lt; 11 g/dl (SDHR: 3.56), and opportunistic infections (OIs) (SDHR: 3.65). For TB treatment LTFU, significant predictors were rural residence (SDHR: 0.11), divorced (SDHR: 2.81), widowed (SDHR: 5.92), BMI &lt; 18.5 (SDHR: 0.41), ambulatory functional status (SDHR: 2.59), adverse drug effects (SDHR: 2.87), and poor ART adherence (SDHR: 5.72). Considering errors in competing events, ART LTFU was higher among rural dwellers, individuals with advanced disease, nutritional deficits, or adverse drug effects requiring prioritised, multifaceted interventions. Targeted strategies such as intensified monitoring, adherence counselling, nutritional support, proactive management of drug-related side effects, marital instability, OIs and poor ART adherence should be integrated into the existing ART/TB program to mitigate LTFU.</p>
<section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Time to LTFU, TB/HIV coinfection, Competing risk regression analysis</p></section><section id="kwd-group2" class="kwd-group"><p><strong>Subject terms:</strong> Infectious diseases, Antimicrobial therapy</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par23">The coinfection of tuberculosis (TB) and human immunodeficiency virus (HIV) poses significant challenges in treatment and case management<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>,<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a></sup>, with coinfected adults facing higher risks of poor outcomes compared to single infections<sup><a href="#CR3" class="usa-link" aria-describedby="CR3">3</a></sup>. Contributing factors include drug interactions between anti-TB and antiretroviral therapy (ART) that reduce efficacy, increase toxicity, and exacerbate inflammatory syndromes<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>,<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a></sup>. To address these challenges, the World Health Organization (WHO)recommends careful medication selection, dosing adjustments<sup><a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>,<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a></sup>, and integrated strategies such as patient education, counselling, and comprehensive support services<sup><a href="#CR8" class="usa-link" aria-describedby="CR8">8</a></sup>, alongside close monitoring and collaboration between HIV and TB clinicians to ensure coordinated care<sup><a href="#CR9" class="usa-link" aria-describedby="CR9">9</a></sup>. Treatment adherence remains critical but is complicated by polypharmacy, overlapping side effects, and drug-drug interactions<sup><a href="#CR10" class="usa-link" aria-describedby="CR10">10</a></sup>. Despite global successes, such as an estimated 53 million deaths averted through treatment, significant gaps in care and prevention persist, particularly in high-burden regions like Ethiopia, which reports a TB incidence rate of 140/100,000 people<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a></sup>.</p>
<p id="Par24">Lost to follow-up (LTFU)rates vary widely across regions: ART LTFU ranges from 4.5 to 42% in Sub-Saharan Africa (SSA)<sup><a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>–<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a></sup>, 18.2% in Latin America<sup><a href="#CR23" class="usa-link" aria-describedby="CR23">23</a></sup>, and 4.5–10.22/1000 person-Years of observation [PYOs] in Ethiopia<sup><a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>–<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a></sup>, while TB treatment LTFU spans 3.6% in Namibia<sup><a href="#CR29" class="usa-link" aria-describedby="CR29">29</a></sup> to 21.2% in Ethiopia<sup><a href="#CR30" class="usa-link" aria-describedby="CR30">30</a></sup>. Key predictors of LTFU include sociodemographic factors (e.g., rural residence, male sex, divorced/widowed marital status)<sup><a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>,<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup>, clinical indicators [e.g., advanced HIV disease<sup><a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>,<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a></sup>, CD4 count &lt; 200 cells/µL, anaemia (haemoglobin ≤ 11.0 g/dl)and OIs)<sup><a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>,<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>,<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a></sup>, and systemic barriers (e.g., poor adherence, adverse drug reactions, food insecurity, and fragmented TB/HIV services)<sup><a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>–<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a></sup>. Paradoxically, adverse drug events may reduce LTFU risk by necessitating closer clinical oversight<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup>.</p>
<p id="Par25">Analysing competing risk data, where patients may experience mutually exclusive outcomes such as LTFU from ART or TB treatment, is complex and susceptible to error. Competing risk analysis is essential to avoid bias and overestimation of predictor effects on time to LTFU from ART or TB treatment. These models appropriately account for mutually exclusive events, where the occurrence of one event precludes others<sup><a href="#CR36" class="usa-link" aria-describedby="CR36">36</a></sup>. For instance, a patient who becomes LTFU from ART cannot subsequently become LTFU from TB treatment.</p>
<p id="Par26">Unlike the Kaplan-Meier method, which treats other events as censored and may thus lead to effect estimates, competing risk models, specifically subdistribution hazard regression models (SDHRMs), utilise the subdistribution hazard function (SDHF) and estimate the cumulative incidence function for each event<sup><a href="#CR17" class="usa-link" aria-describedby="CR17">17</a></sup>. This approach provides more accurate estimates of predictor effects related to time to LTFU, aiding in clinical and policy decisions<sup><a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>,<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a></sup>. Many prior studies have employed the Kaplan-Meier method, which neglects competing risks and can lead to biased conclusions. The use of SDHRMs is crucial to mitigate such biases and improve prognostic modelling<sup><a href="#CR17" class="usa-link" aria-describedby="CR17">17</a></sup>.</p>
<p id="Par27">This study investigated predictors of time to LTFU among adults with TB/HIV coinfection in Ethiopia using a competing risk framework. In addition to previously studied predictors, it incorporated novel variables, such as occupation, viral load, pain assessment and management, and fluconazole preventive therapy (FPT), which were often omitted in earlier survival analyses.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Study design, study area and period</h3>
<p id="Par28">This retrospective follow-up study utilised data from multiple health facilities in Bahir Dar, Ethiopia, spanning 28 June 2017 to 27 June 2022. Bahir Dar is the capital of the Amhara National Regional State, located 565 km northwest of Addis Ababa. According to the 2022 population projection by the Ethiopian Statistical Agency (ESA)<sup><a href="#CR39" class="usa-link" aria-describedby="CR39">39</a></sup>, the city has a population of 422,850, including 215,654 females. The study area comprises 13 governmental health facilities (3 hospitals, 10 health centres) and 4 private hospitals, alongside over 20 private clinics. Among these, 9 health centres and 3 public hospitals operate as ART centres. Five health centres and two public hospitals were selected for inclusion based on their initiation of ART services by or before 28 June 2017. These facilities provide primary, secondary, and tertiary care, including specialised HIV/AIDS and TB management and treatment services. The study sites serve a diverse population within the city and outside the city administration, such as West Gojjam, East Gojjam, Awi, South Gondar, and Central Gondar zones, as well as neighbouring regions.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Source, study population, and eligibility criteria</h3>
<p id="Par29">The source population comprised all adult patients (aged 15 years or older) with TB/HIV coinfection receiving both anti-TB treatment and ART follow-up at TB/ART clinics within public health facilities in Bahir Dar City. The study population included adults (≥ 15 years) with TB/HIV coinfection who underwent treatment at selected TB/HIV clinics in these facilities between June 28, 2017, and June 27, 2022. The study unit consisted of individual patient follow-up records (folders). Inclusion criteria required patients to be aged ≥ 15 years, confirmed TB/HIV-coinfected, and receiving both ART and anti-TB treatment at the selected facilities during the study period. Patients were excluded if they had incomplete medical records, undocumented treatment outcomes (e.g., unknown transfer status or final disposition), and concurrent ART and TB LTFU outcomes. Concurrent ART and TB LTFU outcomes are excluded to avoid the potential overlapping of events of interest (ART LTFU) and competing events (TB LTFU).</p></section><section id="Sec5"><h3 class="pmc_sec_title">Study variables</h3>
<section id="Sec6"><h4 class="pmc_sec_title">Outcomes</h4>
<p id="Par30">This study evaluated time to LTFU from ART and anti-TB treatment as competing outcome variables. LTFU from ART was defined as missing clinic follow-ups for ≥ 3 consecutive months, while LTFU from anti-TB treatment was defined as missing treatment for ≥ 8 consecutive weeks. The events of interest (ART LTFU) and competing events (TB LTFU) are considered if the occurrence of the two events is not simultaneous (if an individual experiences ART LTFU, but s/he no longer experiences TB LTFU at the same time point during our follow-up period). Outcomes were categorised as follows: 1 (LTFU from ART, the event of interest), 2 (LTFU from anti-TB treatment, the competing event), or 0 (censored, including death, treatment completion, cure, or other discontinuations).</p></section><section id="Sec7"><h4 class="pmc_sec_title">Predictors</h4>
<p id="Par31">The study included three categories of predictors: (1) socioeconomic factors (sex, age, religion, education, occupation, residence, marital status); (2) baseline clinical characteristics (BMI, functional status, WHO HIV/AIDS stages, CD4 count, haemoglobin level); and (3) diagnosis- and treatment-related factors (adverse drug events, opportunistic infections (OIs), TB category, TB treatment completion, isoniazid preventive therapy (IPT), cotrimoxazole preventive therapy (CPT), baseline viral load, pain assessment/management, ART adherence, and fluconazole preventive therapy (FPT). These variables were analysed to identify their associations with competing risks of LTFU in TB/HIV coinfected adults.</p></section></section><section id="Sec8"><h3 class="pmc_sec_title">Operational definitions</h3>
<section id="Sec9"><h4 class="pmc_sec_title">TB/HIV coinfection</h4>
<p id="Par32">Refers to the concurrent presence of HIV and TB infections (40).</p></section><section id="Sec10"><h4 class="pmc_sec_title">Lost to follow-up (LTFU)</h4>
<p id="Par33">Was defined as interrupting anti-TB treatment for ≥ 8 consecutive weeks after ≥ 4 weeks of therapy<sup><a href="#CR40" class="usa-link" aria-describedby="CR40">40</a></sup>or missing ART appointments for &gt; 90 days<sup><a href="#CR41" class="usa-link" aria-describedby="CR41">41</a></sup>.</p></section><section id="Sec11"><h4 class="pmc_sec_title">Adherence to ART</h4>
<p id="Par34">Was categorized as good (&gt; 95% adherence: &lt;2 missed doses/30 or &lt; 3/60 doses), fair (85–94%: 2–4 missed/30 or 4–9/60 doses), or poor (&lt; 85%: ≥5 missed/30 or ≥ 10/60 doses), as documented by clinicians<sup><a href="#CR41" class="usa-link" aria-describedby="CR41">41</a></sup>.</p></section><section id="Sec12"><h4 class="pmc_sec_title">Opportunistic infections (OIs) included</h4>
<p id="Par35">Any diagnosed OI other than TB.</p></section><section id="Sec13"><h4 class="pmc_sec_title">Haemoglobin levels</h4>
<p id="Par36">Were classified as anaemic (≤ 11.0 g/dl) or normal (&gt; 11.0 g/dl), irrespective of sex or pregnancy<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup>.</p></section><section id="Sec14"><h4 class="pmc_sec_title">Time to LTFU</h4>
<p id="Par37">Was calculated in months from ART or anti-TB initiation until discontinuation. E<strong>vents</strong>: was LTFU from ART or anti-TB treatment during the study period (June 28, 2017–June 27, 2022).</p></section><section id="Sec15"><h4 class="pmc_sec_title">Censored</h4>
<p id="Par38">Patients were censored if they died, remained in care, or were transferred to other facilities.</p></section><section id="Sec16"><h4 class="pmc_sec_title">Survival status</h4>
<p id="Par39">Was categorised as LTFU or censored based on clinical records.</p></section></section><section id="Sec17"><h3 class="pmc_sec_title">Sample size determination</h3>
<p id="Par40">The required sample size was calculated using the Freedman method of proportional event allocation<sup><a href="#CR42" class="usa-link" aria-describedby="CR42">42</a></sup>, which accounts for the probability of the event as 1− (ps1 (t) + qs2 (t)), where n denotes the sample size, <em>Zα</em>/2 (1.96 at α = 5%), and <em>β</em> (1.282 for 90% power). Assuming equal allocation between groups (p = q = 0.5), hazard ratios (HRs) from prior studies were incorporated. Using Stata version 14’s power log-rank command with parameters including a hazard ratio of 0.451, 90% power, and a withdrawal probability of 0.1, separate sample sizes were computed for five predictors (haemoglobin, adverse drug events, opportunistic infections, TB treatment completion, and isoniazid preventive therapy (IPT) identified as statistically significant in earlier research<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup>. The largest calculated sample size (214) was selected, adjusted for a design effect of 2 to accommodate multistage sampling variability, and increased by 10% to account for incomplete records, yielding a final sample size of 471.</p></section><section id="Sec18"><h3 class="pmc_sec_title">Sampling techniques</h3>
<p id="Par41">We employed a multistage stratified random sampling technique to select participants from seven public health facilities in Bahir Dar City. Medical registration numbers (MRNs) of patients enrolled in ART or TB follow-up programs were compiled from facility registries spanning June 28, 2017, to June 27, 2022. All eligible MRNs within each facility were catalogued, and proportional sample sizes were allocated to each health facility to ensure representative sampling. Using Microsoft Excel’s randomisation function, MRNs were randomly selected from these stratified lists. A total of 471 medical records were included in the study, distributed as follows: 135 from Felege Hiwot Comprehensive Specialised Hospital (FHCSH), 82 from Bahir Dar Health Centre (HC), 72 from Han HC, 69 from Addis Alem Primary Hospital (APH), 54 from Shimbet HC, 39 from Abay HC, and 20 from Tis-Abay HC. This approach ensured geographic and institutional diversity while maintaining methodological rigour in participant selection (Fig. <a href="#Fig1" class="usa-link">1</a>).</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365281_41598_2025_15985_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e76/12365281/668e7dbe40e6/41598_2025_15985_Fig1_HTML.jpg" loading="lazy" id="d33e535" height="411" width="669" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Schematic representation of the sampling procedure used to select 471 coinfected adults in public health facilities in Bahir-Dar city, Amhara, Ethiopia: 2023.</p></figcaption></figure></section><section id="Sec19"><h3 class="pmc_sec_title">Data extraction procedures</h3>
<p id="Par43">We developed structured checklists aligned with the variables of interest to systematically extract data from TB/ART patient charts and Smart Care registries. Trained healthcare professionals external to the selected facilities conducted the data extraction using a standardised tool. The manuscript’s corresponding authors supervised the process daily, verifying completeness, consistency, and accuracy through cross-verification. To mitigate data gaps, records lost during tracing or patients with undetermined ART/TB status were systematically replaced with nearby records, maintaining the integrity of the dataset.</p></section><section id="Sec20"><h3 class="pmc_sec_title">Data quality control</h3>
<p id="Par44">Data quality was ensured throughout tool development, data extraction, coding, entry, cleaning, and analysis. A structured checklist based on the data elements to be recorded on patient charts, registries and follow-up forms was prepared before data extraction. The data extractors and supervisors received one day of training on the data extraction methods. Health professionals with experience in TB and/or ART clinics were recruited. Each day, completed checklists were reviewed for completeness, accuracy, and clarity, with necessary corrections provided the following morning.</p></section><section id="Sec21"><h3 class="pmc_sec_title">Data processing and analysis</h3>
<p id="Par45">The extracted data were initially coded, cleaned, and entered into EPI-data version 4.6<sup><a href="#CR43" class="usa-link" aria-describedby="CR43">43</a></sup>. To address missing data, multiple imputation techniques were employed because we had 12.3% missing data across the dataset of our key variables, including critical laboratory parameters such as viral load and CD4 count.Specifically, we directly compared results from the imputed dataset with those from a complete case analysis (CCA). The CCA approach, which excluded participants with missing data (<em>n</em> = 413), yielded less precise estimates (e.g., wider confidence intervals) and demonstrated clinically meaningful differences in effect sizes for key predictors. Descriptive statistics were conducted using Stata version 14<sup><a href="#CR44" class="usa-link" aria-describedby="CR44">44</a></sup>, while RStudio(We adjusted the version (starting from 4.3.0, then 4.3.1, 4.3.2, and so on) to accommodate the dependencies required by different packages)<sup><a href="#CR45" class="usa-link" aria-describedby="CR45">45</a></sup> software was utilised for estimating cumulative incidence curves and performing multivariable analysis.</p>
<p id="Par46">In the presence of competing risks, standard survival methods such as the Kaplan-Meier estimator are inadequate, as they inherently censor competing events and overestimate the probability of the event of interest. Instead, cumulative incidence functions (CIFs) were utilised to account for the interdependence of event types, where the occurrence of one event (e.g., anti-TB treatment LTFU) alters the probability of observing the primary event (ART LTFU). The CIF quantifies the probability of an individual experiencing a specific event (e.g., ART LTFU) by time “t”, conditional on not having experienced any prior event. This approach explicitly acknowledges that individuals experiencing competing events remain in the risk set for the primary event, ensuring unbiased estimation.</p>
<p id="Par47">Given the study’s focus on ART LTFU as the primary outcome, with anti-TB treatment LTFU as a competing risk, the Fine and Gray subdistribution hazard regression model (FGSDHRM) was used to directly model the CIF. Unlike cause-specific hazard models, FGSDHRM accounts for the cumulative effect of covariates on the subdistribution hazard function (SDHF), which reflects the instantaneous risk of the primary event among those who have not yet experienced it or are still at risk despite competing events. This is critical in settings where competing events are informative and non-negligible.</p>
<p id="Par48">After checking the proportional subdistribution hazard assumption via the cumulative sum of residuals, CIF plots, and modified Schoenfeld residuals, we fitted a multivariable Fine-Gray subdistribution hazard regression model (FGSDHRM) to assess the impact of covariates, age, sex, residence, marital status, religion, occupation, baseline BMI, functional status, WHO stage, CD4 count, haemoglobin level, adverse drug events, pain management, opportunistic infections, TB type, TB treatment completion, IPT, ART adherence, and viral load, on the subdistribution hazard for LTFU from ART versus anti-TB treatment. Covariates with bivariable <em>p</em> ≤ 0.25 were entered into the multivariable model, and those with <em>p</em> &lt; 0.05 were deemed significant.</p>
<p id="Par49">Model fit was assessed via cross-validated calibration curves, which showed close agreement between predicted and observed CIFs, and discrimination was quantified by an AUC of 0.888 (88.8%). A low Brier score of 3.4% further indicated excellent overall performance<sup><a href="#CR46" class="usa-link" aria-describedby="CR46">46</a></sup>. Finally, subdistribution hazard ratios with 95% confidence intervals were reported as statistically significant predictors of time to LTFU in the final FGSDHRM.</p></section></section><section id="Sec22"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec23"><h3 class="pmc_sec_title">Baseline sociodemographic characteristics and LTFU rates of participants</h3>
<p id="Par50">We included 471 co-infected adults, with a median age of 38 years (an interquartile rangeof 32–47) and an age range of 16 to 78 years. Females constituted slightly more than half of the participants, and approximately seven in ten experienced the event of interest (Table <a href="#Tab1" class="usa-link">1</a>).</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Baseline sociodemographic characteristics of TB/HIV-coinfected adults at last follow-up status from 2017—2022 (<em>n</em> = 471).</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Covariates</th>
<th align="left" colspan="1" rowspan="1">ARTLTFU, No (%)</th>
<th align="left" colspan="1" rowspan="1">Censored, No (%)</th>
</tr></thead>
<tbody>
<tr><td align="left" colspan="3" rowspan="1">Residence</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Urban</td>
<td align="left" colspan="1" rowspan="1">19(29.23%)</td>
<td align="left" colspan="1" rowspan="1">324(79.80%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Rural</td>
<td align="left" colspan="1" rowspan="1">46(70.77%)</td>
<td align="left" colspan="1" rowspan="1">82(20.20%)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Age</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Median(IQR)(year)</td>
<td align="left" colspan="1" rowspan="1">36(33–41)</td>
<td align="left" colspan="1" rowspan="1">39(32–48)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Sex</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Male</td>
<td align="left" colspan="1" rowspan="1">19(29.23%)</td>
<td align="left" colspan="1" rowspan="1">206(50.74%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Female</td>
<td align="left" colspan="1" rowspan="1">46 (70.77%)</td>
<td align="left" colspan="1" rowspan="1">200(49.26%)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Religion</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Orthodox</td>
<td align="left" colspan="1" rowspan="1">54(83.08%)</td>
<td align="left" colspan="1" rowspan="1">300(73.89%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Muslim</td>
<td align="left" colspan="1" rowspan="1">5(7.69)</td>
<td align="left" colspan="1" rowspan="1">63(15.52)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Other*</td>
<td align="left" colspan="1" rowspan="1">6(9.23)</td>
<td align="left" colspan="1" rowspan="1">43(10.59%)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Marital status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Single</td>
<td align="left" colspan="1" rowspan="1">20(30.77%)</td>
<td align="left" colspan="1" rowspan="1">90(22.17%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Married</td>
<td align="left" colspan="1" rowspan="1">25(38.46%)</td>
<td align="left" colspan="1" rowspan="1">204(50.25%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Divorced</td>
<td align="left" colspan="1" rowspan="1">16(24.62%)</td>
<td align="left" colspan="1" rowspan="1">82(20.20%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Widowed</td>
<td align="left" colspan="1" rowspan="1">4(6.15%)</td>
<td align="left" colspan="1" rowspan="1">30(7.39%)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Educational level</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No-education</td>
<td align="left" colspan="1" rowspan="1">12(18.46%)</td>
<td align="left" colspan="1" rowspan="1">99(24.38%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Primary</td>
<td align="left" colspan="1" rowspan="1">18(27.69%)</td>
<td align="left" colspan="1" rowspan="1">83(20.44%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Secondary</td>
<td align="left" colspan="1" rowspan="1">28(43.08%)</td>
<td align="left" colspan="1" rowspan="1">188(46.31%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tertiary</td>
<td align="left" colspan="1" rowspan="1">3(4.62%)</td>
<td align="left" colspan="1" rowspan="1">17(4.19%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Diploma &amp; above</td>
<td align="left" colspan="1" rowspan="1">4(6.15%)</td>
<td align="left" colspan="1" rowspan="1">19(4.68%)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Occupational status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Governmental</td>
<td align="left" colspan="1" rowspan="1">12(18.46%)</td>
<td align="left" colspan="1" rowspan="1">69(17.00%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Nongovernmental</td>
<td align="left" colspan="1" rowspan="1">7(10.77%)</td>
<td align="left" colspan="1" rowspan="1">60(14.78%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Merchant</td>
<td align="left" colspan="1" rowspan="1">10(15.38%)</td>
<td align="left" colspan="1" rowspan="1">76(18.72%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Housewife</td>
<td align="left" colspan="1" rowspan="1">4(6.15%)</td>
<td align="left" colspan="1" rowspan="1">51(12.56%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Daily labourer</td>
<td align="left" colspan="1" rowspan="1">17(26.15%)</td>
<td align="left" colspan="1" rowspan="1">60(14.78%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Unemployed</td>
<td align="left" colspan="1" rowspan="1">9(13.85%)</td>
<td align="left" colspan="1" rowspan="1">56(84.62%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Other**</td>
<td align="left" colspan="1" rowspan="1">6(9.23%)</td>
<td align="left" colspan="1" rowspan="1">34(8.37%)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p33"><p>Other*=protestant and Catholic, Other**=Farmer and driver.</p></div></div></section></section><section id="Sec24"><h3 class="pmc_sec_title">Baseline clinical, diagnosis and treatment characteristics of participants</h3>
<p id="Par53">Among the participants, 88.3% had a baseline BMI below the national threshold for adequate nutrition (BMI &lt; 18.5 kg/m<sup>2</sup>), and 83.08% of these individuals experienced the event of interest. Out of the participants, 435 (92.36%) reported no adverse drug effects, and 10(15.38%) experienced the event of interest (Table <a href="#Tab2" class="usa-link">2</a>).</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Baseline clinical, diagnosis and treatment characteristics of coinfected adults at the last follow-up status in Bahir-Dar City public health facilities, amhara, ethiopia: 2017–2022.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Covariates</th>
<th align="left" colspan="1" rowspan="1">ARTLTFU, No. (%)</th>
<th align="left" colspan="1" rowspan="1">Censored, No. (%)</th>
</tr></thead>
<tbody>
<tr><td align="left" colspan="3" rowspan="1">Baseline BMI</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt; 18.5</td>
<td align="left" colspan="1" rowspan="1">54(83.08)</td>
<td align="left" colspan="1" rowspan="1">362(89.16)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">&gt;=18.5</td>
<td align="left" colspan="1" rowspan="1">11(16.92)</td>
<td align="left" colspan="1" rowspan="1">44(10.84)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Baseline functional status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Working</td>
<td align="left" colspan="1" rowspan="1">25(38.46)</td>
<td align="left" colspan="1" rowspan="1">286(70.44)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ambulatory</td>
<td align="left" colspan="1" rowspan="1">20(30.77)</td>
<td align="left" colspan="1" rowspan="1">85(20.94)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bedridden</td>
<td align="left" colspan="1" rowspan="1">20(30.77)</td>
<td align="left" colspan="1" rowspan="1">35(8.62)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Baseline WHO clinical signs</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">stage I</td>
<td align="left" colspan="1" rowspan="1">10(15.38)</td>
<td align="left" colspan="1" rowspan="1">165(40.64)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">stage II</td>
<td align="left" colspan="1" rowspan="1">5(7.69 )</td>
<td align="left" colspan="1" rowspan="1">66(16.26)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">stage III</td>
<td align="left" colspan="1" rowspan="1">19(29.23)</td>
<td align="left" colspan="1" rowspan="1">131(32.27)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">stage IV</td>
<td align="left" colspan="1" rowspan="1">31(47.69)</td>
<td align="left" colspan="1" rowspan="1">44(10.84)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Baseline CD4 count</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt; 200</td>
<td align="left" colspan="1" rowspan="1">32(49.23)</td>
<td align="left" colspan="1" rowspan="1">80( 19.70)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">&gt;=200</td>
<td align="left" colspan="1" rowspan="1">33(50.77)</td>
<td align="left" colspan="1" rowspan="1">326(80.30)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Baseline Hgb</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt; 11</td>
<td align="left" colspan="1" rowspan="1">51(78.46)</td>
<td align="left" colspan="1" rowspan="1">121(29.88)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">&gt;=11</td>
<td align="left" colspan="1" rowspan="1">14(21.54)</td>
<td align="left" colspan="1" rowspan="1">284(70.12)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Adverse drug effect</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">10(15.38)</td>
<td align="left" colspan="1" rowspan="1">26(6.40)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">55(84.62)</td>
<td align="left" colspan="1" rowspan="1">380(93.60)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Baseline viral load</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Undetected</td>
<td align="left" colspan="1" rowspan="1">43(66.15)</td>
<td align="left" colspan="1" rowspan="1">308(75.86)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Detected</td>
<td align="left" colspan="1" rowspan="1">22(33.85)</td>
<td align="left" colspan="1" rowspan="1">98(24.14)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Pain assessment &amp; management</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No-pain</td>
<td align="left" colspan="1" rowspan="1">62(95.38)</td>
<td align="left" colspan="1" rowspan="1">399(98.28)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Others*</td>
<td align="left" colspan="1" rowspan="1">3(4.62)</td>
<td align="left" colspan="1" rowspan="1">7(1.72)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Opportunistic infections</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">48(73.85)</td>
<td align="left" colspan="1" rowspan="1">113(27.83)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">17(26.15 )</td>
<td align="left" colspan="1" rowspan="1">293(72.17)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TB type</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PTB</td>
<td align="left" colspan="1" rowspan="1">11(16.92)</td>
<td align="left" colspan="1" rowspan="1">197(48.52)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EPTB</td>
<td align="left" colspan="1" rowspan="1">54(83.08)</td>
<td align="left" colspan="1" rowspan="1">209(51.48)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">TB treatment completion</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">50(76.92)</td>
<td align="left" colspan="1" rowspan="1">363(89.41)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">15(23.08)</td>
<td align="left" colspan="1" rowspan="1">43(10.59)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">IPT</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Given</td>
<td align="left" colspan="1" rowspan="1">44(67.69)</td>
<td align="left" colspan="1" rowspan="1">122(30.05)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not given</td>
<td align="left" colspan="1" rowspan="1">21(32.31)</td>
<td align="left" colspan="1" rowspan="1">284(69.95)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">CPT</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Given</td>
<td align="left" colspan="1" rowspan="1">55(84.62)</td>
<td align="left" colspan="1" rowspan="1">356(87.68)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not given</td>
<td align="left" colspan="1" rowspan="1">10(15.38)</td>
<td align="left" colspan="1" rowspan="1">50(12.32)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">ART drug adherence</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Good</td>
<td align="left" colspan="1" rowspan="1">36(55.38)</td>
<td align="left" colspan="1" rowspan="1">349(85.96)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fair</td>
<td align="left" colspan="1" rowspan="1">13(20.00)</td>
<td align="left" colspan="1" rowspan="1">33(8.13)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Poor</td>
<td align="left" colspan="1" rowspan="1">16(24.62)</td>
<td align="left" colspan="1" rowspan="1">24(5.91)</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">FPT</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Given</td>
<td align="left" colspan="1" rowspan="1">16(24.62)</td>
<td align="left" colspan="1" rowspan="1">100(24.63)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not given</td>
<td align="left" colspan="1" rowspan="1">49(75.38)</td>
<td align="left" colspan="1" rowspan="1">306(75.37)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p37"><p><em>PBT</em> pulumonary TB, <em>EPTB</em> extrapulumonary TB, <em>IPT</em> isoniazid preventive therapy, <em>CPT</em> co-trimoxazole preventive therapy, <em>FPT</em> fluconazole preventive therapy.</p></div></div></section></section><section id="Sec25"><h3 class="pmc_sec_title">The incidence and median survival time for LTFU from anti-TB treatment or ART among coinfected adults</h3>
<p id="Par56">Among the participants, 13.80% experienced ART LTFU as the primary event of interest, while 11.04% encountered anti-TB treatment LTFU as a competing event. The incidence of ART LTFU was 3.90 cases per 1000 person-months of observation (PMOs), and the incidence of anti-TB treatment LTFU was approximately 19.17 cases per 1000 PMOs. Additionally, 70.77% of the LTFU cases occurred among females, with an incidence rate of 5.62 new cases per 1000 PMOs.</p>
<p id="Par57">We recorded a total of 16,666.86 PMOs for ART and 2,724.43 PMOs for anti-TB treatment follow-up. The duration of ART follow-up ranged from 0.93 to 69.6 months, whereas the anti-TB treatment was from 0.4 to 8 months. Due to significant censoring, the median survival time was indeterminable. To prevent underestimating survival time, we used the restricted mean survival time (RMST), which offers a more precise estimate. The overall RMST was 59.97 months (95% CI 57.29–62.64) for ART LTFU patients and 7.41 months (95% CI 7.26–7.57) for anti-TB treatment LTFU. The RMST to ART LTFU was longer for males (64.69 months) than for females (51.31 months) (Table <a href="#Tab3" class="usa-link">3</a>).</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Incidence and RMST to LTFU in predictors among TB/HIV-coinfected adults in Bahir Dar public health facilities from 28 June 2017 to 27 June 2022.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Covariates</th>
<th align="left" colspan="1" rowspan="1">PMOs</th>
<th align="left" colspan="1" rowspan="1">No. of events#</th>
<th align="left" colspan="1" rowspan="1">Rate/1000 (95% CI)</th>
<th align="left" colspan="1" rowspan="1">RMST(95%CI)</th>
<th align="left" colspan="1" rowspan="1">Gray’s test</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em> value</th>
</tr></thead>
<tbody>
<tr><td align="left" colspan="7" rowspan="1">Sex</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Male</td>
<td align="left" colspan="1" rowspan="1">8459.4</td>
<td align="left" colspan="1" rowspan="1">19</td>
<td align="left" colspan="1" rowspan="1">2.25 (0.0014–0.0035)</td>
<td align="left" colspan="1" rowspan="1">64.69(62.59–66.80)</td>
<td align="left" rowspan="2" colspan="1">12.39</td>
<td align="left" rowspan="2" colspan="1">0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Female</td>
<td align="left" colspan="1" rowspan="1">8188.43</td>
<td align="left" colspan="1" rowspan="1">46</td>
<td align="left" colspan="1" rowspan="1">5.62 (0.0042–0.0075)</td>
<td align="left" colspan="1" rowspan="1">51.31(48.98–53.64)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Residence</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Urban</td>
<td align="left" colspan="1" rowspan="1">4298.34</td>
<td align="left" colspan="1" rowspan="1">47</td>
<td align="left" colspan="1" rowspan="1">10.93(0.0082–0.0145)</td>
<td align="left" colspan="1" rowspan="1">65.03(62.36–67.71)</td>
<td align="left" rowspan="2" colspan="1">72.33</td>
<td align="left" rowspan="2" colspan="1">0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Rural</td>
<td align="left" colspan="1" rowspan="1">12349.49</td>
<td align="left" colspan="1" rowspan="1">18</td>
<td align="left" colspan="1" rowspan="1">1.46(0.0009–0.0023)</td>
<td align="left" colspan="1" rowspan="1">44.15(40.43–47.86)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Marital status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Single</td>
<td align="left" colspan="1" rowspan="1">3872.34</td>
<td align="left" colspan="1" rowspan="1">20</td>
<td align="left" colspan="1" rowspan="1">5.16 (0.0033–0.0080)</td>
<td align="left" colspan="1" rowspan="1">58.71(54.53–62.90)</td>
<td align="left" rowspan="4" colspan="1">15.34</td>
<td align="left" rowspan="4" colspan="1">0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Married</td>
<td align="left" colspan="1" rowspan="1">8440.5</td>
<td align="left" colspan="1" rowspan="1">25</td>
<td align="left" colspan="1" rowspan="1">2.96(0 0.0020- 0.0044)</td>
<td align="left" colspan="1" rowspan="1">56.57(54.64–58.50)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Divorced</td>
<td align="left" colspan="1" rowspan="1">3066.23</td>
<td align="left" colspan="1" rowspan="1">16</td>
<td align="left" colspan="1" rowspan="1">5.22(0.0032–0.0085)</td>
<td align="left" colspan="1" rowspan="1">51.97(48.22–55.74)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Widowed</td>
<td align="left" colspan="1" rowspan="1">1268.76</td>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">3.15(0.0012–0.0084)</td>
<td align="left" colspan="1" rowspan="1">54.03(48.68–59.39)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">BMI</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">&gt;=18.5</td>
<td align="left" colspan="1" rowspan="1">1686.94</td>
<td align="left" colspan="1" rowspan="1">11</td>
<td align="left" colspan="1" rowspan="1">6.52 (0.0036-0.0118)</td>
<td align="left" colspan="1" rowspan="1">49.39(43.97–54.79)</td>
<td align="left" rowspan="2" colspan="1">15.98</td>
<td align="left" rowspan="2" colspan="1">0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt; 18.5</td>
<td align="left" colspan="1" rowspan="1">14960.89</td>
<td align="left" colspan="1" rowspan="1">54</td>
<td align="left" colspan="1" rowspan="1">3.61(0.0028–0.0047)</td>
<td align="left" colspan="1" rowspan="1">60.59(57.87–63.31)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Functional status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Working</td>
<td align="left" colspan="1" rowspan="1">11670.36</td>
<td align="left" colspan="1" rowspan="1">24</td>
<td align="left" colspan="1" rowspan="1">2.06 (0.0014–0.0031)</td>
<td align="left" colspan="1" rowspan="1">63.64(60.62–66.66)</td>
<td align="left" rowspan="3" colspan="1">35.35</td>
<td align="left" rowspan="3" colspan="1">0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ambulatory</td>
<td align="left" colspan="1" rowspan="1">3130.69</td>
<td align="left" colspan="1" rowspan="1">21</td>
<td align="left" colspan="1" rowspan="1">6.71(0.0044–0.0103)</td>
<td align="left" colspan="1" rowspan="1">49.52(45.57–53.47)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bedridden</td>
<td align="left" colspan="1" rowspan="1">1846.78</td>
<td align="left" colspan="1" rowspan="1">20</td>
<td align="left" colspan="1" rowspan="1">10.83(0.0069–0.0168)</td>
<td align="left" colspan="1" rowspan="1">44.71(39.20-50.22)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">WHO stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stage I</td>
<td align="left" colspan="1" rowspan="1">7251.13</td>
<td align="left" colspan="1" rowspan="1">10</td>
<td align="left" colspan="1" rowspan="1">1.38(0 0.00074-0.0026)</td>
<td align="left" colspan="1" rowspan="1">66.48(64.60-68.36)</td>
<td align="left" rowspan="4" colspan="1">60.5</td>
<td align="left" rowspan="4" colspan="1">0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stage II</td>
<td align="left" colspan="1" rowspan="1">2271.02</td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">2.20 (0.0009-0.0053)</td>
<td align="left" colspan="1" rowspan="1">55.95(52.65–59.26)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stage III</td>
<td align="left" colspan="1" rowspan="1">5026.78</td>
<td align="left" colspan="1" rowspan="1">19</td>
<td align="left" colspan="1" rowspan="1">3.78(0.0024–0.0059)</td>
<td align="left" colspan="1" rowspan="1">53.50(50.79–56.19)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stage IV</td>
<td align="left" colspan="1" rowspan="1">2098.9</td>
<td align="left" colspan="1" rowspan="1">31</td>
<td align="left" colspan="1" rowspan="1">14.77(0 0.0104-0.0210)</td>
<td align="left" colspan="1" rowspan="1">40.64(35.41–45.86)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">CD4</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt; 200</td>
<td align="left" colspan="1" rowspan="1">3651.96</td>
<td align="left" colspan="1" rowspan="1">32</td>
<td align="left" colspan="1" rowspan="1">8.76(0.0062–0.0124)</td>
<td align="left" colspan="1" rowspan="1">47.18(43.19–51.17)</td>
<td align="left" rowspan="2" colspan="1">25.93</td>
<td align="left" rowspan="2" colspan="1">0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">&gt;=200</td>
<td align="left" colspan="1" rowspan="1">12995.87</td>
<td align="left" colspan="1" rowspan="1">33</td>
<td align="left" colspan="1" rowspan="1">2.54(0.0018–0.0036)</td>
<td align="left" colspan="1" rowspan="1">62.64(59.64–65.64)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Hgb level</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt; 11</td>
<td align="left" colspan="1" rowspan="1">5422.14</td>
<td align="left" colspan="1" rowspan="1">51</td>
<td align="left" colspan="1" rowspan="1">9.41(0.0071–0.0124)</td>
<td align="left" colspan="1" rowspan="1">46.34(43.09–49.58)</td>
<td align="left" rowspan="2" colspan="1">58.06</td>
<td align="left" rowspan="2" colspan="1">0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">&gt;=11</td>
<td align="left" colspan="1" rowspan="1">11223.69</td>
<td align="left" colspan="1" rowspan="1">14</td>
<td align="left" colspan="1" rowspan="1">1.25(0.00074–0.0021)</td>
<td align="left" colspan="1" rowspan="1">66.50(64.91–68.10)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Adverse drug effect</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">1093.62</td>
<td align="left" colspan="1" rowspan="1">11</td>
<td align="left" colspan="1" rowspan="1">10.06(0.0056–0.0182)</td>
<td align="left" colspan="1" rowspan="1">60.84(58.14–63.54)</td>
<td align="left" rowspan="2" colspan="1">12.62</td>
<td align="left" rowspan="2" colspan="1">&lt; 0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">15554.21</td>
<td align="left" colspan="1" rowspan="1">54</td>
<td align="left" colspan="1" rowspan="1">3.47(0.0026–0.0045)</td>
<td align="left" colspan="1" rowspan="1">43.40(36.75–50.05)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Viral load</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Undetected</td>
<td align="left" colspan="1" rowspan="1">12905.67</td>
<td align="left" colspan="1" rowspan="1">43</td>
<td align="left" colspan="1" rowspan="1">3.33(0.0025–0.0045)</td>
<td align="left" colspan="1" rowspan="1">60.78(57.45–64.11)</td>
<td align="left" rowspan="2" colspan="1">4.37</td>
<td align="left" rowspan="2" colspan="1">0.037*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Detected</td>
<td align="left" colspan="1" rowspan="1">3742.16</td>
<td align="left" colspan="1" rowspan="1">22</td>
<td align="left" colspan="1" rowspan="1">5.88(0.0039–0.0089)</td>
<td align="left" colspan="1" rowspan="1">51.11(47.52–54.69)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Pain Mgt.</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No pain</td>
<td align="left" colspan="1" rowspan="1">16430.59</td>
<td align="left" colspan="1" rowspan="1">62</td>
<td align="left" colspan="1" rowspan="1">3.77(0.0029–0.0048)</td>
<td align="left" colspan="1" rowspan="1">60.23(57.56–62.89)</td>
<td align="left" rowspan="2" colspan="1">4.03</td>
<td align="left" rowspan="2" colspan="1">0.044*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Other**</td>
<td align="left" colspan="1" rowspan="1">217.24</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">13.81(0.0045–0.0428)</td>
<td align="left" colspan="1" rowspan="1">35.66(20.54–50.77)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">OI##</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">5203.41</td>
<td align="left" colspan="1" rowspan="1">49</td>
<td align="left" colspan="1" rowspan="1">9.42(0.0071–0.0125)</td>
<td align="left" colspan="1" rowspan="1">66.29(64.71–67.87)</td>
<td align="left" rowspan="2" colspan="1">60.03</td>
<td align="left" rowspan="2" colspan="1">&lt; 0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">11432.79</td>
<td align="left" colspan="1" rowspan="1">16</td>
<td align="left" colspan="1" rowspan="1">1.39 (0.0009–0.0023)</td>
<td align="left" colspan="1" rowspan="1">46.64(43.23–50.04)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">TB type</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">PTB</td>
<td align="left" colspan="1" rowspan="1">7287.12</td>
<td align="left" colspan="1" rowspan="1">11</td>
<td align="left" colspan="1" rowspan="1">1.51(0.0008–0.0027)</td>
<td align="left" colspan="1" rowspan="1">66.21(64.26–68.15)</td>
<td align="left" rowspan="2" colspan="1">20.4</td>
<td align="left" rowspan="2" colspan="1">0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EPTB</td>
<td align="left" colspan="1" rowspan="1">9360.71</td>
<td align="left" colspan="1" rowspan="1">54</td>
<td align="left" colspan="1" rowspan="1">5.77(0.0044–0.0075)</td>
<td align="left" colspan="1" rowspan="1">51.93(49.61–54.27)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">TB Rx completion</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">15198.55</td>
<td align="left" colspan="1" rowspan="1">49</td>
<td align="left" colspan="1" rowspan="1">3.22(0.0024–0.0043)</td>
<td align="left" colspan="1" rowspan="1">61.48(58.75–64.21)</td>
<td align="left" rowspan="2" colspan="1">5.75</td>
<td align="left" rowspan="2" colspan="1">0.016*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">1449.28</td>
<td align="left" colspan="1" rowspan="1">16</td>
<td align="left" colspan="1" rowspan="1">11.04 (0.0068–0.0180)</td>
<td align="left" colspan="1" rowspan="1">45.07(39.39–50.75)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">IPT</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Given</td>
<td align="left" colspan="1" rowspan="1">5263.9</td>
<td align="left" colspan="1" rowspan="1">44</td>
<td align="left" colspan="1" rowspan="1">8.36(0.0062–0.0112)</td>
<td align="left" colspan="1" rowspan="1">47.26(44.08–50.44)</td>
<td align="left" rowspan="2" colspan="1">36.48</td>
<td align="left" rowspan="2" colspan="1">0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not given</td>
<td align="left" colspan="1" rowspan="1">11383.93</td>
<td align="left" colspan="1" rowspan="1">21</td>
<td align="left" colspan="1" rowspan="1">1.84(0.0012–0.0028)</td>
<td align="left" colspan="1" rowspan="1">64.24(61.48–66.98)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">CPT</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Given</td>
<td align="left" colspan="1" rowspan="1">14509.53</td>
<td align="left" colspan="1" rowspan="1">55</td>
<td align="left" colspan="1" rowspan="1">3.79(0.0029–0.0049)</td>
<td align="left" colspan="1" rowspan="1">54.98(53.31–56.65)</td>
<td align="left" rowspan="2" colspan="1">10.8</td>
<td align="left" rowspan="2" colspan="1">0.001*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not given</td>
<td align="left" colspan="1" rowspan="1">2138.3</td>
<td align="left" colspan="1" rowspan="1">10</td>
<td align="left" colspan="1" rowspan="1">4.68(0.0025–0.0087)</td>
<td align="left" colspan="1" rowspan="1">59.07(53.31–64.82)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">ART drug adherence</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Good</td>
<td align="left" colspan="1" rowspan="1">14155.87</td>
<td align="left" colspan="1" rowspan="1">35</td>
<td align="left" colspan="1" rowspan="1">2.47(0.0018–0.0034)</td>
<td align="left" colspan="1" rowspan="1">62.78(59.81–65.75)</td>
<td align="left" rowspan="3" colspan="1">34.87</td>
<td align="left" rowspan="3" colspan="1">0.003*</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fair</td>
<td align="left" colspan="1" rowspan="1">1617.62</td>
<td align="left" colspan="1" rowspan="1">13</td>
<td align="left" colspan="1" rowspan="1">8.04(0.0047–0.0138)</td>
<td align="left" colspan="1" rowspan="1">47.98(42.95–53.01)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Poor</td>
<td align="left" colspan="1" rowspan="1">874.34</td>
<td align="left" colspan="1" rowspan="1">17</td>
<td align="left" colspan="1" rowspan="1">19.44(0.0121–0.0313)</td>
<td align="left" colspan="1" rowspan="1">35.76(27.86–43.67)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">FPT</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Given</td>
<td align="left" colspan="1" rowspan="1">4180.17</td>
<td align="left" colspan="1" rowspan="1">16</td>
<td align="left" colspan="1" rowspan="1">3.83(0.0023–0.0062)</td>
<td align="left" colspan="1" rowspan="1">53.78(50.61–56.95)</td>
<td align="left" rowspan="2" colspan="1">0.057</td>
<td align="left" rowspan="2" colspan="1">0.811</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not given</td>
<td align="left" colspan="1" rowspan="1">12467.66</td>
<td align="left" colspan="1" rowspan="1">49</td>
<td align="left" colspan="1" rowspan="1">3.93(0.0030–0.0052)</td>
<td align="left" colspan="1" rowspan="1">59.49(56.19–62.78)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Overall LTFU rate</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">ARTLTFU</td>
<td align="left" colspan="1" rowspan="1">16,666.9</td>
<td align="left" colspan="1" rowspan="1">65</td>
<td align="left" colspan="1" rowspan="1">3.90(0.0031–0.0050)</td>
<td align="left" colspan="1" rowspan="1">59.97(57.29–62.64)</td>
<td align="left" colspan="1" rowspan="1">
<strong>%</strong>
</td>
<td align="left" colspan="1" rowspan="1">
<strong>%</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TBLTFU</td>
<td align="left" colspan="1" rowspan="1">2724.4</td>
<td align="left" colspan="1" rowspan="1">52</td>
<td align="left" colspan="1" rowspan="1">19.17(0.0146–0.0252)</td>
<td align="left" colspan="1" rowspan="1">7.41(7.26–7.57)</td>
<td align="left" colspan="1" rowspan="1">
<strong>%</strong>
</td>
<td align="left" colspan="1" rowspan="1">
<strong>%</strong>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p42">
<p>#N<em>o</em> ART LTFU events.</p>
<p>##IO other than TB.</p>
<p>Rx = Treatment.</p>
<p>*Indicates the significantly associated categorical variables at <em>p</em> &lt; 0.05 in Gray’s test for equality of survivor functions with a 95% confidence level.</p>
<p>% they are outcomes, not categorical predictors.</p>
<p>Other WHO step 1, 2 &amp; 3.</p>
</div></div></section></section><section id="Sec26"><h3 class="pmc_sec_title">Cumulative incidence differences among categorical covariates among adult TB/HIV-coinfected patients</h3>
<p id="Par65">The statistical analysis revealed significant differences between categories of sex, residence, marital status, BMI, functional status, WHO clinical stages, CD4 counts, Hgb levels, viral load, pain management, presence of OIs other than TB, TB type, TB treatment completion, IPT, adverse drug effects, and ART drug adherence. However, no significant differences were found in the categories of religion, educational level, occupational status, CPT, and FPT (Table <a href="#Tab3" class="usa-link">3</a>).</p>
<p id="Par66">The cumulative incidence of ART LTFU was estimated to be 5.4, 8.2, 11.2, 15.6, and 28.9% at 12, 24, 36, 48, and 60 months of follow-up, respectively. In contrast, the cumulative incidence of anti-TB treatment LTFU was estimated to be 3.7, 5.5, 7.5, 12.5, and 23.6% at the same follow-up intervals. These estimates indicate a persistent increase in the probability of experiencing both events over time among Coinfected adults.</p>
<p id="Par67">We use the CIF curve to compare the CIF differences between categories of covariates using Gray’s test. The overall incidence of the event of interest exceeded that of the competing event. Both events began to rise at the study’s onset, with the expected incidence of both events increasing from the start-up to 60 months, after which it remained stable until the end of the final follow-up period (Fig. <a href="#Fig2" class="usa-link">2</a>a).</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365281_41598_2025_15985_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e76/12365281/00a323561243/41598_2025_15985_Fig2_HTML.jpg" loading="lazy" id="d33e1869" height="687" width="669" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>CIF plot of outcomes and predictor variabls by LTFU incidence among coinfected adults in Bahir Dar, 2017–2022.</p></figcaption></figure><p id="Par69">There was a significant difference in the incidence of LTFU between rural and urban settings for both treatments. Specifically, the incidence of experiencing the event of interest was higher in rural areas than in urban areas. Conversely, the incidence of competing events was higher in urban areas than in rural areas (Fig. <a href="#Fig2" class="usa-link">2</a>b).</p>
<p id="Par70">Concerning anti-TB treatment, there were significant differences in LTFU incidence based on baseline BMI. Compared with their counterparts, individuals with a BMI &lt; 18.5 kg/m² had a lower incidence of experiencing competing events, although there was no statistically significant difference in LTFU from ART (Fig. <a href="#Fig2" class="usa-link">2</a>c).</p>
<p id="Par71">Significant differences in LTFU incidence were observed between categories of baseline haemoglobin (Hgb) levels for ART. Individuals with baseline Hgb levels &lt; 11 g/dl had a greater incidence of experiencing the event of interest than those with higher Hgb levels. However, there was no significant difference in LTFU from anti-TB treatment based on baseline Hgb levels (Fig. <a href="#Fig2" class="usa-link">2</a>d).</p>
<p id="Par72">There was a notable difference in LTFU incidence between categories of adverse drug effects from ART. Individuals with a history of adverse drug effects had a higher incidence of the event of interest than those without such a history. However, no significant difference in LTFU incidence was observed for patients receiving anti-TB treatment because of adverse drug effects (Fig. <a href="#Fig2" class="usa-link">2</a>e).</p>
<p id="Par73">Additionally, there was a significant difference in LTFU incidence between categories of OIs from ART. Individuals with a history of at least one OI other than TB experienced a higher incidence of the event of interest than those with no history of OIs. No significant difference in LTFU incidence was found for anti-TB treatment based on OI history (Fig. <a href="#Fig2" class="usa-link">2</a>f).</p></section><section id="Sec27"><h3 class="pmc_sec_title">Predictors of time to LTFU from ART and anti-TB treatment among adults with TB/HIV coinfections in the final SDHRM</h3>
<p id="Par74">We applied the Fine and Gray subdistribution hazard regression model (FGSDHRM) to analyse the competing risks of LTFU among TB/HIV co-infected adults. This approach allowed us to account for the presence of competing events, providing a more accurate estimation of the cumulative incidence of LTFU.</p>
<p id="Par75">Our analysis identified four variables as significant prognostic factors for LTFU from ART. These factors were determined based on their SHRs and corresponding 95% CIs, indicating their impact on the risk of ART LTFU over time. Similarly, seven variables were found to be significant predictors of LTFU from anti-TB treatment. These variables demonstrated statistically significant associations with the risk of LTFU, as evidenced by their SHRs and 95% CIs.</p>
<p id="Par76">The identification of these prognostic factors through FGSDHRM underscores the importance of considering competing risks in survival analysis, particularly in the context of TB/HIV co-infection, where patients are at risk of multiple, mutually exclusive events. For ART LTFU, significant predictors included a rural residence, WHO clinical stage IV, Hgb level &lt; 11 g/dl and a history of opportunistic infections other than TB were associated with an increased incidence of ART LTFU. For anti-TB treatment LTFU, significant predictors were age, rural residence, and baseline BMI &lt; 18.5 kg/m², which are associated with a decreased incidence, whereas marital status (divorced and widowed), baseline functional status (ambulatory), adverse drug effects, and ART drug adherence are associated with an increased incidence ant-TB treatment LTFU.</p>
<p id="Par77">Table <a href="#Tab4" class="usa-link">4</a> presents the SDH ratios, P values, and 95% confidence intervals for the selected covariates derived from the FGSDHRM for different types of treatment, LTFU.</p>
<section class="tw xbox font-sm" id="Tab4"><h4 class="obj_head">Table 4.</h4>
<div class="caption p"><p>Multivariable competing risk analysis of predictors of LTFU among TB/HIV-coinfected adults: 2017–2022.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Covariates</th>
<th align="left" colspan="1" rowspan="1">Category</th>
<th align="left" colspan="1" rowspan="1">a<sub>1</sub>SDHR (95% CI)</th>
<th align="left" colspan="1" rowspan="1">
<em>p</em>-value</th>
<th align="left" colspan="1" rowspan="1">a<sub>2</sub>SDHR (95% CI)</th>
<th align="left" colspan="1" rowspan="1">
<em>p</em>-value</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="2" rowspan="1">Age</td>
<td align="left" colspan="1" rowspan="1">0.98(0.95–1.01)</td>
<td align="left" colspan="1" rowspan="1">0.190</td>
<td align="left" colspan="1" rowspan="1">0.97( 0.94-1.00)</td>
<td align="left" colspan="1" rowspan="1">
<strong>0.047*</strong>
</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Residence</td>
<td align="left" colspan="1" rowspan="1">Rural</td>
<td align="left" colspan="1" rowspan="1">3.39 (1.56–7.41)</td>
<td align="left" colspan="1" rowspan="1">
<strong>0.002*</strong>
</td>
<td align="left" colspan="1" rowspan="1">0.11(0.04–0.32)</td>
<td align="center" colspan="1" rowspan="1">
<strong>0.001**</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Urban</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Sex</td>
<td align="left" colspan="1" rowspan="1">Female</td>
<td align="left" colspan="1" rowspan="1">1.77(0.80–3.89)</td>
<td align="left" colspan="1" rowspan="1">0.16</td>
<td align="left" colspan="1" rowspan="1">1.34(0.61–2.92)</td>
<td align="center" colspan="1" rowspan="1">0.47</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Male</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">0.62</td>
</tr>
<tr>
<td align="left" rowspan="4" colspan="1">Marital status</td>
<td align="left" colspan="1" rowspan="1">Single</td>
<td align="left" colspan="1" rowspan="1">0.88(0.39–1.98)</td>
<td align="left" colspan="1" rowspan="1">0.75</td>
<td align="left" colspan="1" rowspan="1">1.14(0.42–3.11)</td>
<td align="center" colspan="1" rowspan="1">0.81</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Married</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Divorced</td>
<td align="left" colspan="1" rowspan="1">0.85(0.43–1.70)</td>
<td align="left" colspan="1" rowspan="1">0.65</td>
<td align="left" colspan="1" rowspan="1">2.81(1.01–7.82)</td>
<td align="center" colspan="1" rowspan="1">
<strong>0.049*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Widowed</td>
<td align="left" colspan="1" rowspan="1">0.78(0.26–2.35)</td>
<td align="left" colspan="1" rowspan="1">0.66</td>
<td align="left" colspan="1" rowspan="1">5.92(2.17–16.15)</td>
<td align="center" colspan="1" rowspan="1">
<strong>0.001**</strong>
</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Baseline BMI</td>
<td align="left" colspan="1" rowspan="1">&lt; 18.5</td>
<td align="left" colspan="1" rowspan="1">1.49(0.53–4.20)</td>
<td align="left" colspan="1" rowspan="1">0.44</td>
<td align="left" colspan="1" rowspan="1">0.41(0.20–0.82)</td>
<td align="center" colspan="1" rowspan="1">
<strong>0.012*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">&gt;=18.5</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Baseline</td>
<td align="left" colspan="1" rowspan="1">Working</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Functional</td>
<td align="left" colspan="1" rowspan="1">Ambulatory</td>
<td align="left" colspan="1" rowspan="1">1.41(0.65–3.05)</td>
<td align="left" colspan="1" rowspan="1">0.38</td>
<td align="left" colspan="1" rowspan="1">2.59(1.19–5.69)</td>
<td align="center" colspan="1" rowspan="1">
<strong>0.017*</strong>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Status</td>
<td align="left" colspan="1" rowspan="1">Bedridden</td>
<td align="left" colspan="1" rowspan="1">1.32(0.55–3.17)</td>
<td align="left" colspan="1" rowspan="1">0.54</td>
<td align="left" colspan="1" rowspan="1">0.66(0.19–2.28)</td>
<td align="center" colspan="1" rowspan="1">0.52</td>
</tr>
<tr>
<td align="left" rowspan="4" colspan="1">Baseline WHO stage</td>
<td align="left" colspan="1" rowspan="1">Stage I</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stage II</td>
<td align="left" colspan="1" rowspan="1">1.05(0.24–4.52)</td>
<td align="left" colspan="1" rowspan="1">0.95</td>
<td align="left" colspan="1" rowspan="1">1.68(0.56–5.06)</td>
<td align="center" colspan="1" rowspan="1">0.36</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stage III</td>
<td align="left" colspan="1" rowspan="1">1.94(0.74–5.13)</td>
<td align="left" colspan="1" rowspan="1">0.18</td>
<td align="left" colspan="1" rowspan="1">1.56(0.70–3.48)</td>
<td align="center" colspan="1" rowspan="1">0.27</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stage IV</td>
<td align="left" colspan="1" rowspan="1">2.88(1.01–8.26)</td>
<td align="left" colspan="1" rowspan="1">
<strong>0.049*</strong>
</td>
<td align="left" colspan="1" rowspan="1">1.23(0.29–5.13)</td>
<td align="center" colspan="1" rowspan="1">0.78</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Baseline Hgb level</td>
<td align="left" colspan="1" rowspan="1">&lt; 11gm/dl</td>
<td align="left" colspan="1" rowspan="1">3.56(1.75–7.24)</td>
<td align="left" colspan="1" rowspan="1">
<strong>0.001**</strong>
</td>
<td align="left" colspan="1" rowspan="1">0.69(0.31–1.52)</td>
<td align="center" colspan="1" rowspan="1">0.35</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">&gt;=11gm/dl</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Adverse Drug event</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">0.68(0.21–2.17)</td>
<td align="left" colspan="1" rowspan="1">0.51</td>
<td align="left" colspan="1" rowspan="1">2.87(1.23–6.73)</td>
<td align="center" colspan="1" rowspan="1">
<strong>0.015*</strong>
</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Opportunistic Infection</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">3.65(1.77–7.53)</td>
<td align="left" colspan="1" rowspan="1">
<strong>0.001**</strong>
</td>
<td align="left" colspan="1" rowspan="1">0.97(0.42–2.25)</td>
<td align="center" colspan="1" rowspan="1">0.95</td>
</tr>
<tr>
<td align="left" rowspan="3" colspan="1">ART Drug adherence</td>
<td align="left" colspan="1" rowspan="1">Good</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.61(0.18–2.07)</td>
<td align="center" colspan="1" rowspan="1">0.43</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fair</td>
<td align="left" colspan="1" rowspan="1">1.16(0.44–3.03)</td>
<td align="left" colspan="1" rowspan="1">0.77</td>
<td align="left" colspan="1" rowspan="1">1.93(0.66–5.61)</td>
<td align="center" colspan="1" rowspan="1">0.23</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Poor</td>
<td align="left" colspan="1" rowspan="1">1.91(0.58–6.26)</td>
<td align="left" colspan="1" rowspan="1">0.28</td>
<td align="left" colspan="1" rowspan="1">5.72(2.36–13.84)</td>
<td align="center" colspan="1" rowspan="1">
<strong>0.001*</strong>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p id="Par78">The analysis revealed that the SDHR for coinfected adults residing in rural areas is 3.39 times that of those living in urban areas, indicating that the cumulative incidence of ART LTFU is significantly higher among rural dwellers (SDHR = 3.39, 95% CI: 1.56–7.41). Furthermore, the SDHR indicates that coinfected adults with a baseline WHO HIV/AIDS clinical stage IV have a 2.88 times higher cumulative incidence of ART LTFU compared to those with a baseline stage I, suggesting that individuals with stage IV disease are at significantly higher risk of LTFU (SDHR = 2.88, 95% CI 1.01–8.26).</p>
<p id="Par79">Additionally, coinfected adults with a baseline Hgb level of less than 11 g/dl is 3.56 times higher than those with a baseline Hgb level of 11 g/dl or higher, indicating that the cumulative incidence of ART LTFU is significantly higher among those with Hgb levels less than 11 g/dl (SDHR = 3.56, 95% CI 1.75–7.24).</p>
<p id="Par80">Finally, the SDHR for coinfected adults with opportunistic infections (OIs) other than tuberculosis is 3.65 times higher than that for those without OIs other than TB, indicating that the `cumulative incidence of ART LTFU is significantly higher among individuals with OIs other than TB (SDHR = 3.65, 95% CI 1.77–7.53).</p>
<p id="Par81">Based on the analysis, the effects of age were found to be similar for both types of failures (ART and anti-TB treatment LTFU), with no significant impact on LTFU for either treatment (SDHR = 0.98, 95% CI 0.95–1.0, <em>p</em> = 0.19 and SDHR = 0.97, 95% CI 0.94–1.00, <em>p</em> = 0.047, respectively). Compared to their urban counterparts, adults with coinfection residing in rural areas have an 89% lower cumulative incidence of LTFU during anti-TB treatment. This suggests a significantly reduced cumulative incidence of LTFU in rural settings (SHR = 0.11, 95% CI 0.04–0.32).</p>
<p id="Par82">Adults with coinfection who were divorced or widowed experienced a significantly higher cumulative incidence of LTFU during anti-TB treatment compared to those who were married. Specifically, the SDHR indicated that divorced individuals had a 2.81 times higher risk (95% CI: 1.01–7.82](of LTFU, and widowed individuals had a 5.92 times higher risk (95% CI: 2.17–16.15) of LTFU during TB treatment.</p>
<p id="Par83">Individuals with a baseline BMI of less than 18.5 kg/m² have a 59% lower SDH of LTFU during anti-TB treatment compared to those with a BMI of 18.5 kg/m² or greater. This indicates a lower cumulative incidence of LTFU among those with lower BMIs, as reflected by an SDHR of 0.41(95% CI: 0.20–0.82). Individuals with an ambulatory baseline functional status are 2.59 times more likely to experience LTFU from anti-TB treatment compared to those with a working baseline functional status. This indicates a higher cumulative incidence of anti-TB treatment LTFU among those with ambulatory functional status, as reflected by an SDHR of 2.59 (95% CI: 1.19–5.69).</p>
<p id="Par84">Poor ART drug adherence was associated with a 5.72-fold greater likelihood of experiencing LTFU from anti-TB treatment compared to good ART drug adherence, indicating a significantly higher cumulative incidence of anti-TB treatment LTFU (SHR = 5.72,95% CI: 2.36–13.84). Finally, Individuals who experienced adverse drug effects were 2.87 times more likely to be LTFU on anti-TB treatment compared to those who did not experience adverse drug effects. This indicates a higher incidence of LTFU among individuals with adverse drug effects. This suggests that the association is statistically significant and that adverse drug effects are a substantial risk factor for LTFU (SDHR = 2.87, 95% CI 1.23–6.73) (Table <a href="#Tab4" class="usa-link">4</a>).</p></section></section><section id="Sec28"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par86">In our study, we identified the predictors of time to LTFU from ART and TB treatment using LTFU from TB treatment as competing events and the cumulative incidence of time to LTFU from ART, the event of interest. Accordingly, individuals residing in rural areas, those classified as WHO stage IV, those with haemoglobin levels below 11 g/dl, and those with opportunistic infections were identified as statistically significant prognostic predictors of ART LTFU. Similarly, rural residence, being divorced or widowed, ambulatory functional status, adverse drug effects, and poor ART adherence were significant prognostic predictors of TB treatment LTFU.</p>
<p id="Par87">Our analysis accounted for drawbacks or failures of the conventional time-to-event survival analysis method, which were addressed in the literature<sup><a href="#CR47" class="usa-link" aria-describedby="CR47">47</a></sup>, and studies show that conventional survival hazard regression models fail to account for multiple competing events when estimating the effect sizes of predictors<sup><a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>,<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a></sup>.</p>
<p id="Par88">The median survival time for LTFU from anti-TB or ART among adults with TB/HIV-coinfected patients is undetermined; however, the RMST of ART LTFU and anti-TB treatment LTFU among coinfected adult patients were estimated and found to be 59.97 and 7.41 months, respectively, but these findings could not be compared with those of other studies because other studies reported median survival time.</p>
<p id="Par89">The incidence of ART LTFU was 3.9 LTFU cases per 1000 PMOs or 4.7/100 PYOs (95% CI: 3–5), which is lower than that reported in studies conducted in Zimbabwe (5.75 per 100 PYOs)<sup><a href="#CR49" class="usa-link" aria-describedby="CR49">49</a></sup>, Uganda (7.5 per 100 PYOs)<sup><a href="#CR50" class="usa-link" aria-describedby="CR50">50</a></sup> and Ethiopia (10.9 per 100 PYOs)<sup><a href="#CR27" class="usa-link" aria-describedby="CR27">27</a></sup>. These differences could be attributed to variations in sample sizes, follow-up durations, study environments, and the characteristics of the populations involved. In this context, the follow-up periods of the Ugandan<sup><a href="#CR50" class="usa-link" aria-describedby="CR50">50</a></sup> and previous Ethiopian studies<sup><a href="#CR27" class="usa-link" aria-describedby="CR27">27</a></sup> were three and four years, respectively. The follow-up period of our study was five years. In addition, in our study, we used a competing risk analysis approach, which prevents upward estimation of the standard survival analysis estimates. The incidence rate of LTFU during anti-TB treatment was 19.17 per 1000 PMOs (95% CI: 14.6–25.2). This result is lower than a study conducted in the Sheka Zone health centres, in southern Ethiopia, which reported incidence rates of 27.3 per 1000 PMOs but higher than findings in the same place in a general hospital, which reported incidence rates of 9.6 per 1000 PMOs<sup><a href="#CR51" class="usa-link" aria-describedby="CR51">51</a></sup>. It is also higher than the rate observed in a study from Gondar, Ethiopia, where the incidence rate was 6.47 per 1000 PMOs<sup><a href="#CR52" class="usa-link" aria-describedby="CR52">52</a></sup>. The above variations might be due to differences in sample sizes, study settings, and population characteristics<sup><a href="#CR52" class="usa-link" aria-describedby="CR52">52</a></sup>. In this context, the sample size and population characteristics in the previous study included 332 individuals with drug-resistant tuberculosis but 471 TB/HIV Coinfected adults, and the previous study was performed at a specialised hospital, whereas our study was done in both hospitals and health centres. Therefore, there may be health service delivery differences across settings.</p>
<p id="Par90">Residence in rural areas, baseline WHO clinical stage IV, baseline haemoglobin levels less than 11 g/dl, and a history of opportunistic infections other than TB have been identified as potential prognostic factors for ART LTFU. Our study revealed that rural residency significantly increases the risk of ART LTFU, a finding that is consistent with research conducted in sub-Saharan Africa, including Debre Markos and Oromiya in Ethiopia<sup><a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>–<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a></sup>. This association may be attributed to the extended travel times required for rural residents to access healthcare facilities, which can hinder regular clinic visits and medication pickups, thereby increasing the risk of LTFU<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>,<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a></sup>. Additionally, rural populations often experience lower income levels, limited employment opportunities, and undernutrition, which can further impact their ability to access and maintain care. Furthermore, the lack of strong community-based support systems in rural areas may negatively influence treatment adherence and retention in care<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>,<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>,<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a></sup>.</p>
<p id="Par91">In this study, patients with a baseline WHO clinical stage IV disease were at a higher risk of ART LTFU. This result is supported by research carried out in Ethiopia’s Oromia region, along with studies from Tanzania and Uganda<sup><a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>,<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>,<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a></sup>. These studies suggest that individuals with advanced HIV/AIDS (WHO clinical stage IV) may experience more severe symptoms and treatment side effects, which can affect their adherence to ART and ongoing engagement in care. Additionally, patients with advanced disease often require more intensive healthcare support. Those residing in rural areas or with limited access to healthcare facilities may encounter difficulties in obtaining necessary care, leading to increased instances of LTFU<sup><a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>,<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a></sup>. Furthermore, patients with advanced HIV/AIDS may face heightened social and economic challenges, such as discrimination, stigma, poverty, and insufficient social support, which can exacerbate their difficulties in maintaining care and adhering to treatment<sup><a href="#CR60" class="usa-link" aria-describedby="CR60">60</a></sup>. Advanced disease status is also associated with a risk of mortality and can contribute to ART LTFU due to adverse effects such as drug toxicity, treatment failure, and drug resistance, ultimately compromising patient survival<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup>.</p>
<p id="Par92">Coinfected adult patients with a baseline haemoglobin level of less than 11 g/dl are at increased risk of LTFU from ART. This result aligns with studies carried out in Ethiopia’s Tigray region<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup>. Low haemoglobin levels are often indicative of disease severity, disability, and overall impairment<sup><a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>,<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a></sup>. They may also signal a serious illness, contributing to symptoms that complicate adherence to ART and the continuation of care. Additionally, low haemoglobin is a common comorbidity among ART patients, exacerbating symptoms such as weakness and fatigue<sup><a href="#CR31" class="usa-link" aria-describedby="CR31">31</a></sup>. For patients coinfected with TB/HIV, the need for multiple medications to address HIV, TB, and anaemia can result in a significant treatment burden. This burden, coupled with the complex side effects of these drugs, may adversely impact a patient’s ability to adhere to ART and maintain engagement in care, potentially increasing the incidence of LTFU<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup>.</p>
<p id="Par93">Patients who have experienced OIs other than TB tend to have a higher incidence of LTFU from ART. This result is in line with studies carried out in the Tigray region of Ethiopia<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup>. Despite the availability of ART<sup><a href="#CR62" class="usa-link" aria-describedby="CR62">62</a></sup>, OIs continue to be a significant cause of hospitalisation and advanced disease, potentially leading to increased LTFU and higher healthcare utilisation. OIs can undermine adherence to treatment and raise concerns about adverse effects, thereby increasing the risk of LTFU. Evidence suggests that the presence of OIs during ART follow-up may indicate therapy failure or poor response, contributing to LTFU by exacerbating the overall burden of illness and increasing the frequency of medical visits. Furthermore, poor treatment adherence associated with OIs is linked to the incidence of LTFU and challenges in managing drug adherence<sup><a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>,<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>–<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a></sup>.</p>
<p id="Par94">Age, residence (rural), marital status (divorced and widowed), baseline BMI (BMI &lt; 18.5 kg/m²), baseline functional status (ambulatory), the presence of adverse drug effects, and poor ART drug adherence have been identified as potential prognostic factors for LTFU from anti-TB treatment. In our study, age appeared to have a comparable effect on the incidence of LTFU across both treatments. However, this finding contrasts with existing scientific evidence suggesting that age can positively influence the risk of LTFU in anti-TB treatment among adults. For example, a retrospective cohort study conducted in Ethiopia indicated that older TB patients experienced higher rates of LTFU than their younger counterparts did<sup><a href="#CR51" class="usa-link" aria-describedby="CR51">51</a></sup>. Similarly, another Ethiopian study reported that TB patients aged 55–64 years were four times more likely to experience LTFU<sup><a href="#CR66" class="usa-link" aria-describedby="CR66">66</a></sup>. Furthermore, a global analysis of LTFU in multidrug-resistant TB (MDR-TB) patients across 22 countries revealed that HIV-positive individuals aged 36–50 years face the highest risk of LTFU<sup><a href="#CR67" class="usa-link" aria-describedby="CR67">67</a></sup>.</p>
<p id="Par95">An increased incidence of LTFU for anti-TB treatment has been observed among coinfected adults, who are divorced or widowed, a finding that is consistent with a study conducted in Central Kenya (40). Prior research on healthcare utilisation and marital status in the Netherlands<sup><a href="#CR68" class="usa-link" aria-describedby="CR68">68</a></sup> has highlighted differences based on marital status. This association may be attributed to several factors, including social support, economic stability, psychological impact, and healthcare access, which are often less favourable for individuals who are divorced or widowed<sup><a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>–<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a></sup>. Additionally, studies in Northwest Ethiopia and India have indicated a significant link between single or divorced marital status and poorer adherence to TB treatment<sup><a href="#CR72" class="usa-link" aria-describedby="CR72">72</a></sup>.</p>
<p id="Par96">A Coinfected adult whose baseline BMI is less than 18.5 kg/m2 (undernutrition) has a decreased incidence of anti-TB treatment LTFU. Research conducted in Taiwan, Peru, Guinea, South Africa, and Ethiopia has demonstrated that underweight patients with TB face a higher risk of LTFU than those with a normal BMI<sup><a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>–<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a></sup>. This elevated risk may be attributed to a combination of factors, including the severity of the disease, economic instability, comorbid health conditions, and treatment adherence<sup><a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>–<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a></sup>. Among coinfected adults, an ambulatory baseline functional status is associated with an increased incidence of LTFU for anti-TB treatment. This observation is consistent with results from a competing risk study carried out in Gondar<sup><a href="#CR27" class="usa-link" aria-describedby="CR27">27</a></sup>. The relationship between ambulatory functional status and lost of follow-up for TB treatment is multifaceted, encompassing factors such as disease severity, adherence to treatment, and access to and support from healthcare services<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>,<a href="#CR73" class="usa-link" aria-describedby="CR73">73</a></sup>.</p>
<p id="Par97">Patients with coinfection who have a history of adverse drug events are at a higher risk of LTFU during anti-TB treatment. The increase in treatment LTFU can be linked to a range of interconnected factors, including adherence to treatment, economic stability, psychological effects, and the availability of healthcare and support services<sup><a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>,<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>,<a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>,<a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>,<a href="#CR79" class="usa-link" aria-describedby="CR79">79</a></sup>. Furthermore, having to manage multiple medications can lead patients to stop taking some drugs, focusing instead on continuing others to lessen the overall medication burden, especially if they perceive one condition as less severe than the other.</p>
<p id="Par98">Finally, a coinfected patient with poor adherence to ART is at increased risk of LTFU from anti-TB treatment. The factors contributing to this increased risk may include adverse drug effects, forgetfulness in medication adherence, prolonged absences from home, missed appointments, lack of transportation, insufficient social support, conflicts with religious beliefs, demands on traditional healers, fear of stigma and discrimination, feelings of hopelessness regarding treatment, inadequate communication between patients and healthcare providers, and interruptions in the availability of medications<sup><a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>,<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a></sup>.</p></section><section id="Sec29"><h2 class="pmc_sec_title">Conclusion</h2>
<p id="Par99">This study investigates the time to lost to follow-up and its predictors among adults co-infected with tuberculosis (TB) and HIV. While the median survival time was undetermined, the restricted mean survival time was 59.97 months. The incidence rates of LTFU were 3.90 and 19.17 per 1,000 PMOs for ART and anti-TB treatment, respectively. The cumulative incidence of LTFU was 13.8% for ART and 11.04% for anti-TB treatment. Notably, the ART LTFU rate (3.9 per 1000 PMOs) was lower than that reported in a previous Ethiopian study (9.1 per 1000 PMOs), while the anti-TB treatment LTFU rate (19.17 per 1,000 PMOs) was higher than that reported in Gondar, Ethiopia (6.47 per 1,000 PMOs).</p>
<p id="Par100">The risk of ART LTFU was significantly higher among individuals living in rural areas, those at WHO stage IV, with haemoglobin levels below 11 g/dl, and those with opportunistic infections. TB treatment LTFU was more prevalent among rural residents, divorced or widowed individuals, and those with ambulatory functional status, adverse drug effects, and poor ART adherence.</p>
<p id="Par101">These findings underscore the need for enhanced care, close monitoring, and regular follow-ups for TB/HIV co-infected adults, particularly those at higher risk of LTFU. Healthcare systems should implement structured counselling, integrated follow-up mechanisms, and intensified monitoring strategies. Strengthening adherence counselling, coordinating multidisciplinary case teams, and ensuring regular supervision and mentoring of health facilities are vital. Collaboration with nongovernmental organisations to align adherence programs with ART and TB services is also recommended.</p>
<section id="Sec30"><h3 class="pmc_sec_title">Strengths and limitations of the study</h3>
<p id="Par102">The study on lost to follow-up from ART and anti-TB treatment was conducted as a multicenter analysis utilising a competing risk framework with the Fine and Gray subdistribution hazard regression model. This approach is advantageous because it mitigates the overestimation commonly associated with Kaplan‒Meier estimates and provides interpretable risk estimates. The Fine and Gray model effectively manages competing risks and aligns with the cumulative incidence of each event type. The analysis accounts for informative censoring and dependent events. This study is pioneering in evaluating the time to LTFU from ART and anti-TB treatment and identifying predictors among coinfected adults using a competing risk analysis.</p>
<p id="Par103">However, the study’s findings should be considered within the context of certain limitations. The use of secondary data precluded the inclusion of significant predictors such as distance from the facility, income level, disclosure status, treatment regimens, and other clinical factors due to inadequate recording. Additionally, the study faced a substantial level of censorship (75.2%), which may affect model stability. However, similar studies have been published with comparable levels of censorship<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>,<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>,<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a></sup>. It is recommended that future researchers conduct prospective or retrospective follow-up studies by including important predictors of ART LTFU that were not addressed in this study, such as income level, distance from a health facility, disclosure status, treatment regimen, and substance use.</p></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>First, I am very grateful to GOD, who always helped me throughout the entire process.Second, I am grateful to Bahir Dar University College of Medicine and Health Sciences School of Public Health for allowing me to perform this research.Third, We would like to appreciate Hossana College of Health Sciences for financial and material support. Finally, I extend my deepest gratitude to the lecturers, families, friends, data extractors, supervisors and Bahir Dar City health department and selected public health facility staff for their valuable support and cooperativeness throughout my thesis work.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>AIDS</dt>
<dd><p id="Par2">Acquired immunodeficiency syndrome</p></dd>
<dt>ART</dt>
<dd><p id="Par3">Anti-retroviral therapy</p></dd>
<dt>BMI</dt>
<dd><p id="Par4">Body mass index</p></dd>
<dt>CD4</dt>
<dd><p id="Par5">Cluster of differentiation 4</p></dd>
<dt>CI</dt>
<dd><p id="Par6">Confidence interval</p></dd>
<dt>CIF</dt>
<dd><p id="Par7">Cumulative incidence function</p></dd>
<dt>CPT</dt>
<dd><p id="Par8">Cotrimoxazole preventive therapy</p></dd>
<dt>FGSDHRM</dt>
<dd><p id="Par9">Fine-gray subdistribution regression hazard model</p></dd>
<dt>FPT</dt>
<dd><p id="Par10">Fluconazole preventive therapy</p></dd>
<dt>Hgb</dt>
<dd><p id="Par11">Haemoglobin</p></dd>
<dt>HIV</dt>
<dd><p id="Par12">Human immunodeficiency virus</p></dd>
<dt>HR</dt>
<dd><p id="Par13">Hazard ratio</p></dd>
<dt>IPT</dt>
<dd><p id="Par14">Isoniazid prophylactic therapy</p></dd>
<dt>LTFU</dt>
<dd><p id="Par15">Lost to follow-up</p></dd>
<dt>OI(s)</dt>
<dd><p id="Par16">Opportunistic infection(s)</p></dd>
<dt>PMOs</dt>
<dd><p id="Par17">Person months of observation</p></dd>
<dt>PYOs</dt>
<dd><p id="Par18">Person years of observation</p></dd>
<dt>RMST</dt>
<dd><p id="Par19">Restricted mean survival time</p></dd>
<dt>SDHF/R</dt>
<dd><p id="Par20">Subdistribution hazard function/ratio</p></dd>
<dt>TB</dt>
<dd><p id="Par21">Tuberculosis</p></dd>
<dt>WHO</dt>
<dd><p id="Par22">World health organisation</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>DR conceived the idea, wrote and presented the proposal, supervised the field work, curated the data, formally analysed the data, drafted and revised the manuscript.HG and AT reviewed the proposal, participated in the data analysis, reviewed the final report and reviewed the draft manuscript.HY reviewed the proposal, participated in the data analysis, reviewed the final report and reviewed the draft manuscript.AZ, TA, and ND reviewed the proposal, participated in the data analysis, reviewed the draft manuscript, and approved it for submission.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>Hossana College of Health Sciences, which is a scholarship grantor, funded the study. The funder has no role in the design, conduct or analysis of the study.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>All the data are available within the manuscript. If additional datasets are required, they can be obtained from the corresponding author upon a reasonable request.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par104">The authors declare no competing interests.</p></section><section id="FPar4"><h3 class="pmc_sec_title">Ethical approval and consent to participate</h3>
<p id="Par105">Due to the retrospective nature of the study, the need to obtain the informed consent was waived by the Institutional Review Board (IRB) of the College of Health Sciences of Bahir Dar University approved the study, with study protocol number 730/2023. The IRB performs following the Declaration of Helsinki, the International Conferences on Harmonisation (ICH) Good Clinical Practice, the WHO Operating Guidelines for Ethical Review Committee and the National Guideline for Research Ethics in Ethiopia. The Amhara Public Health Institute (APHI) reviewed the ethical approval protocols and requested that the selected hospitals and health centres provide records of TB/HIV treatment follow-up data to the authors. Accordingly, the health facilities’ patient charts or ART follow-up forms were used. The name of the patient was not included in the checklist. The data of any patient were not used for other purposes other than for the aim of this study.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Lawn, S. D. &amp; Zumla, A. I. Tuberculosis. <em>Lancet</em><strong>378</strong> (9785), 57–72. (2011).
</cite> [<a href="https://doi.org/10.1016/S0140-6736(10)62173-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21420161/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lawn,%20S.%20D.%20&amp;%20Zumla,%20A.%20I.%20Tuberculosis.%20Lancet378%20(9785),%2057%E2%80%9372.%20(2011)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>WHO G. Global tuberculosis report 2020. <em>Glob. Tuberc. Rep.</em> (2020).</cite>
</li>
<li id="CR3">
<span class="label">3.</span><cite>Organization, W. H. <em>Global Tuberculosis Report 2021: Supplementary Material</em> (World Health Organization, 2022).</cite>
</li>
<li id="CR4">
<span class="label">4.</span><cite>Gurumurthy, P. et al. Decreased bioavailability of Rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. <em>Antimicrob. Agents Chemother.</em><strong>48</strong> (11), 4473–4475 (2004).
</cite> [<a href="https://doi.org/10.1128/AAC.48.11.4473-4475.2004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC525439/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15504887/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gurumurthy,%20P.%20et%20al.%20Decreased%20bioavailability%20of%20Rifampin%20and%20other%20antituberculosis%20drugs%20in%20patients%20with%20advanced%20human%20immunodeficiency%20virus%20disease.%20Antimicrob.%20Agents%20Chemother.48%20(11),%204473%E2%80%934475%20(2004)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>McIlleron, H., Meintjes, G., Burman, W. J. &amp; Maartens, G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. <em>J. Infect. Dis.</em><strong>196</strong> (1), S63–75 (2007).
</cite> [<a href="https://doi.org/10.1086/518655" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17624828/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McIlleron,%20H.,%20Meintjes,%20G.,%20Burman,%20W.%20J.%20&amp;%20Maartens,%20G.%20Complications%20of%20antiretroviral%20therapy%20in%20patients%20with%20tuberculosis:%20drug%20interactions,%20toxicity,%20and%20immune%20reconstitution%20inflammatory%20syndrome.%20J.%20Infect.%20Dis.196%20(1),%20S63%E2%80%9375%20(2007)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Organization, W. H. <em>Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations</em> (World Health Organization, 2016).</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/27559558/" class="usa-link">PubMed</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Tadokera, R. et al. Hypercytokinaemia accompanies HIV–tuberculosis immune reconstitution inflammatory syndrome. <em>Eur. Respir. J.</em><strong>37</strong> (5), 1248–1259 (2011).
</cite> [<a href="https://doi.org/10.1183/09031936.00091010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3242045/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20817712/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tadokera,%20R.%20et%20al.%20Hypercytokinaemia%20accompanies%20HIV%E2%80%93tuberculosis%20immune%20reconstitution%20inflammatory%20syndrome.%20Eur.%20Respir.%20J.37%20(5),%201248%E2%80%931259%20(2011)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Mills, E. J. et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North america: a meta-analysis. <em>Jama</em><strong>296</strong> (6), 679–690 (2006).
</cite> [<a href="https://doi.org/10.1001/jama.296.6.679" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16896111/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mills,%20E.%20J.%20et%20al.%20Adherence%20to%20antiretroviral%20therapy%20in%20sub-Saharan%20Africa%20and%20North%20america:%20a%20meta-analysis.%20Jama296%20(6),%20679%E2%80%93690%20(2006)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Harries, A. D., Zachariah, R. &amp; Lawn, S. D. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. <em>Int. J. Tuberc Lung Dis.</em><strong>13</strong> (1), 6–16 (2009).
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/19105873/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Harries,%20A.%20D.,%20Zachariah,%20R.%20&amp;%20Lawn,%20S.%20D.%20Providing%20HIV%20care%20for%20co-infected%20tuberculosis%20patients:%20a%20perspective%20from%20sub-Saharan%20Africa.%20Int.%20J.%20Tuberc%20Lung%20Dis.13%20(1),%206%E2%80%9316%20(2009)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>CDC. Managing drug interactions in the treatment of HIV-related tuberculosis. <a href="http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm</a> (2013).</cite>
</li>
<li id="CR11">
<span class="label">11.</span><cite>MoH Ethiopia. Guidelines for Clinical and Programmatic Management of TB, TB/HIV, DR-TB and Leprosy in Ethiopia 2021.</cite>
</li>
<li id="CR12">
<span class="label">12.</span><cite>Arnesen, R., Moll, A. P. &amp; Shenoi, S. V. Predictors of lost to follow-up among patients on ART at a rural hospital in KwaZulu-Natal, South Africa. <em>PLoS One</em>. <strong>12</strong> (5), e0177168 (2017).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0177168" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5443492/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28542309/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Arnesen,%20R.,%20Moll,%20A.%20P.%20&amp;%20Shenoi,%20S.%20V.%20Predictors%20of%20lost%20to%20follow-up%20among%20patients%20on%20ART%20at%20a%20rural%20hospital%20in%20KwaZulu-Natal,%20South%20Africa.%20PLoS%20One.%2012%20(5),%20e0177168%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Haas, A. D. et al. Retention and mortality on antiretroviral therapy in sub-Saharan africa: collaborative analyses of HIV treatment programmes. <em>J. Int. AIDS. Soc.</em><strong>21</strong> (2), e25084 (2018).
</cite> [<a href="https://doi.org/10.1002/jia2.25084" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5897849/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29479867/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Haas,%20A.%20D.%20et%20al.%20Retention%20and%20mortality%20on%20antiretroviral%20therapy%20in%20sub-Saharan%20africa:%20collaborative%20analyses%20of%20HIV%20treatment%20programmes.%20J.%20Int.%20AIDS.%20Soc.21%20(2),%20e25084%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Joseph Davey, D. et al. Same-day antiretroviral therapy is associated with increased lost to follow‐up in South African public health facilities: a prospective cohort study of patients diagnosed with HIV. <em>J. Int. AIDS. Soc.</em><strong>23</strong> (6), e25529 (2020).
</cite> [<a href="https://doi.org/10.1002/jia2.25529" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7277782/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32510186/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Joseph%20Davey,%20D.%20et%20al.%20Same-day%20antiretroviral%20therapy%20is%20associated%20with%20increased%20lost%20to%20follow%E2%80%90up%20in%20South%20African%20public%20health%20facilities:%20a%20prospective%20cohort%20study%20of%20patients%20diagnosed%20with%20HIV.%20J.%20Int.%20AIDS.%20Soc.23%20(6),%20e25529%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Khumalo, P. G., Chou, Y. J. &amp; Pu, C. Antiretroviral treatment attrition in swaziland: a population-based study. <em>Epidemiol. Infect.</em><strong>144</strong> (16), 3474–3482 (2016).
</cite> [<a href="https://doi.org/10.1017/S0950268816001813" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9150204/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27545693/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Khumalo,%20P.%20G.,%20Chou,%20Y.%20J.%20&amp;%20Pu,%20C.%20Antiretroviral%20treatment%20attrition%20in%20swaziland:%20a%20population-based%20study.%20Epidemiol.%20Infect.144%20(16),%203474%E2%80%933482%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Legesse, T. et al. Trends of tuberculosis treatment outcomes of notified cases in three refugee camps in sudan: a four-year retrospective analysis, 2014–2017. <em>Sudan. J. Med. Sci.</em><strong>16</strong> (2), 259–275 (2021).</cite> [<a href="https://scholar.google.com/scholar_lookup?Legesse,%20T.%20et%20al.%20Trends%20of%20tuberculosis%20treatment%20outcomes%20of%20notified%20cases%20in%20three%20refugee%20camps%20in%20sudan:%20a%20four-year%20retrospective%20analysis,%202014%E2%80%932017.%20Sudan.%20J.%20Med.%20Sci.16%20(2),%20259%E2%80%93275%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Mugisha, V. et al. Determinants of mortality and lost to follow-up among adults enrolled in HIV care services in Rwanda. <em>PLoS One</em>. <strong>9</strong> (1), e85774 (2014).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0085774" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3893284/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24454931/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mugisha,%20V.%20et%20al.%20Determinants%20of%20mortality%20and%20lost%20to%20follow-up%20among%20adults%20enrolled%20in%20HIV%20care%20services%20in%20Rwanda.%20PLoS%20One.%209%20(1),%20e85774%20(2014)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Nacarapa, E. et al. Predictors of attrition among adults in a rural HIV clinic in Southern mozambique: 18-year retrospective study. <em>Sci. Rep.</em><strong>11</strong> (1), 17897 (2021).
</cite> [<a href="https://doi.org/10.1038/s41598-021-97466-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8429703/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34504234/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nacarapa,%20E.%20et%20al.%20Predictors%20of%20attrition%20among%20adults%20in%20a%20rural%20HIV%20clinic%20in%20Southern%20mozambique:%2018-year%20retrospective%20study.%20Sci.%20Rep.11%20(1),%2017897%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Nansera, D. et al. Mortality and lost to follow-up among tuberculosis and HIV co-infected patients in rural Southwestern Uganda. <em>Int. J. Tuberc. Lung Dis.</em><strong>16</strong> (10), 1371–1376 (2012).
</cite> [<a href="https://doi.org/10.5588/ijtld.11.0589" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22863182/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nansera,%20D.%20et%20al.%20Mortality%20and%20lost%20to%20follow-up%20among%20tuberculosis%20and%20HIV%20co-infected%20patients%20in%20rural%20Southwestern%20Uganda.%20Int.%20J.%20Tuberc.%20Lung%20Dis.16%20(10),%201371%E2%80%931376%20(2012)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Ntabanganyimana, D., Rugema, L., Omolo, J., Nsekuye, O. &amp; Malamba, S. S. Incidence and factors associated with being lost to follow-up among people living with HIV and receiving antiretroviral therapy in nyarugenge the central business district of Kigali city, Rwanda. <em>PLoS One</em>. <strong>17</strong> (10), e0275954 (2022).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0275954" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9562217/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36228004/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ntabanganyimana,%20D.,%20Rugema,%20L.,%20Omolo,%20J.,%20Nsekuye,%20O.%20&amp;%20Malamba,%20S.%20S.%20Incidence%20and%20factors%20associated%20with%20being%20lost%20to%20follow-up%20among%20people%20living%20with%20HIV%20and%20receiving%20antiretroviral%20therapy%20in%20nyarugenge%20the%20central%20business%20district%20of%20Kigali%20city,%20Rwanda.%20PLoS%20One.%2017%20(10),%20e0275954%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Wekesa, P., McLigeyo, A., Owuor, K., Mwangi, J. &amp; Ngugi, E. Survival probability and factors associated with time to lost to follow-up and mortality among patients on antiretroviral treatment in central Kenya. <em>BMC Infect. Dis.</em><strong>22</strong> (1), 522 (2022).
</cite> [<a href="https://doi.org/10.1186/s12879-022-07505-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9171980/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35668350/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wekesa,%20P.,%20McLigeyo,%20A.,%20Owuor,%20K.,%20Mwangi,%20J.%20&amp;%20Ngugi,%20E.%20Survival%20probability%20and%20factors%20associated%20with%20time%20to%20lost%20to%20follow-up%20and%20mortality%20among%20patients%20on%20antiretroviral%20treatment%20in%20central%20Kenya.%20BMC%20Infect.%20Dis.22%20(1),%20522%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Zürcher, K. et al. Outcomes of HIV-positive patients lost to follow‐up in African treatment programmes. <em>Tropical Med. Int. Health</em>. <strong>22</strong> (4), 375–387 (2017).</cite> [<a href="https://doi.org/10.1111/tmi.12843" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5580236/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28102610/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Z%C3%BCrcher,%20K.%20et%20al.%20Outcomes%20of%20HIV-positive%20patients%20lost%20to%20follow%E2%80%90up%20in%20African%20treatment%20programmes.%20Tropical%20Med.%20Int.%20Health.%2022%20(4),%20375%E2%80%93387%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Carriquiry, G. et al. Mortality and lost to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean. <em>J. Int. AIDS Soc.</em><strong>18</strong> (1), 20016 (2015).
</cite> [<a href="https://doi.org/10.7448/IAS.18.1.20016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4499577/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26165322/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Carriquiry,%20G.%20et%20al.%20Mortality%20and%20lost%20to%20follow-up%20among%20HIV-infected%20persons%20on%20long-term%20antiretroviral%20therapy%20in%20Latin%20America%20and%20the%20Caribbean.%20J.%20Int.%20AIDS%20Soc.18%20(1),%2020016%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Dessu, S., Mesele, M., Habte, A. &amp; Dawit, Z. Time until lost to follow-up, incidence, and predictors among adults taking ART at public hospitals in Southern Ethiopia. <em>HIV/AIDS-Res. Palliative Care</em> 205 – 215. (2021).</cite> [<a href="https://doi.org/10.2147/HIV.S296226" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7900442/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33633468/" class="usa-link">PubMed</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Gezae, K. E., Abebe, H. T. &amp; Gebretsadik, L. G. Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, mekelle, ethiopia, 2009–2016: survival model approach. <em>BMC Infect. Dis.</em><strong>19</strong> (1), 107 (2019).
</cite> [<a href="https://doi.org/10.1186/s12879-019-3756-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6360725/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30717705/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gezae,%20K.%20E.,%20Abebe,%20H.%20T.%20&amp;%20Gebretsadik,%20L.%20G.%20Incidence%20and%20predictors%20of%20LTFU%20among%20adults%20with%20TB/HIV%20co-infection%20in%20two%20governmental%20hospitals,%20mekelle,%20ethiopia,%202009%E2%80%932016:%20survival%20model%20approach.%20BMC%20Infect.%20Dis.19%20(1),%20107%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Mekonnen, N., Abdulkadir, M., Shumetie, E., Baraki, A. G. &amp; Yenit, M. K. Incidence and predictors of lost to follow-up among HIV infected adults after initiation of first line anti-retroviral therapy at university of Gondar comprehensive specialized hospital Northwest ethiopia, 2018: retrospective follow up study. <em>BMC Res. Notes</em>. <strong>12</strong> (1), 111 (2019).
</cite> [<a href="https://doi.org/10.1186/s13104-019-4154-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6396485/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30819236/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mekonnen,%20N.,%20Abdulkadir,%20M.,%20Shumetie,%20E.,%20Baraki,%20A.%20G.%20&amp;%20Yenit,%20M.%20K.%20Incidence%20and%20predictors%20of%20lost%20to%20follow-up%20among%20HIV%20infected%20adults%20after%20initiation%20of%20first%20line%20anti-retroviral%20therapy%20at%20university%20of%20Gondar%20comprehensive%20specialized%20hospital%20Northwest%20ethiopia,%202018:%20retrospective%20follow%20up%20study.%20BMC%20Res.%20Notes.%2012%20(1),%20111%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Teshale, A. B., Tsegaye, A. T. &amp; Wolde, H. F. Incidence and predictors of lost to follow up among adult HIV patients on antiretroviral therapy in university of Gondar comprehensive specialized hospital: A competing risk regression modeling. <em>PLoS One</em>. <strong>15</strong> (1), e0227473 (2020).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0227473" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6980595/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31978137/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Teshale,%20A.%20B.,%20Tsegaye,%20A.%20T.%20&amp;%20Wolde,%20H.%20F.%20Incidence%20and%20predictors%20of%20lost%20to%20follow%20up%20among%20adult%20HIV%20patients%20on%20antiretroviral%20therapy%20in%20university%20of%20Gondar%20comprehensive%20specialized%20hospital:%20A%20competing%20risk%20regression%20modeling.%20PLoS%20One.%2015%20(1),%20e0227473%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Tola, H. H., Azar, T., Shojaeizadeh, D. &amp; Garmaroudi, G. Tuberculosis treatment non-adherence and lost to follow up among TB patients with or without HIV in developing countries: a systematic review. <em>Iran. J. Public. Health</em>. <strong>44</strong> (1), 1 (2015).
</cite> [<a href="/articles/PMC4449995/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26060770/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tola,%20H.%20H.,%20Azar,%20T.,%20Shojaeizadeh,%20D.%20&amp;%20Garmaroudi,%20G.%20Tuberculosis%20treatment%20non-adherence%20and%20lost%20to%20follow%20up%20among%20TB%20patients%20with%20or%20without%20HIV%20in%20developing%20countries:%20a%20systematic%20review.%20Iran.%20J.%20Public.%20Health.%2044%20(1),%201%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Kibuule, D. et al. Predictors of lost to follow-up of tuberculosis cases under the DOTS programme in Namibia. <em>ERJ Open. Res.</em><strong>6</strong> (1). (2020).</cite> [<a href="https://doi.org/10.1183/23120541.00030-2019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7073418/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32201689/" class="usa-link">PubMed</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Mekonnen, H. S. &amp; Azagew, A. W. Non-adherence to anti-tuberculosis treatment, reasons and associated factors among TB patients attending at Gondar town health centers, Northwest Ethiopia. <em>BMC Res. Notes</em>. <strong>11</strong> (1), 691 (2018).
</cite> [<a href="https://doi.org/10.1186/s13104-018-3789-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6167840/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30285907/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mekonnen,%20H.%20S.%20&amp;%20Azagew,%20A.%20W.%20Non-adherence%20to%20anti-tuberculosis%20treatment,%20reasons%20and%20associated%20factors%20among%20TB%20patients%20attending%20at%20Gondar%20town%20health%20centers,%20Northwest%20Ethiopia.%20BMC%20Res.%20Notes.%2011%20(1),%20691%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Shroufi, A. et al. Risk of death among those awaiting treatment for HIV infection in zimbabwe: adolescents are at particular risk. <em>J. Int. AIDS Soc.</em><strong>18</strong> (1), 19247 (2015).
</cite> [<a href="https://doi.org/10.7448/IAS.18.1.19247" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4339242/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25712590/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shroufi,%20A.%20et%20al.%20Risk%20of%20death%20among%20those%20awaiting%20treatment%20for%20HIV%20infection%20in%20zimbabwe:%20adolescents%20are%20at%20particular%20risk.%20J.%20Int.%20AIDS%20Soc.18%20(1),%2019247%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Oni, T. et al. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. <em>Thorax</em><strong>66</strong> (8), 669–673 (2011).
</cite> [<a href="https://doi.org/10.1136/thx.2011.160168" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3142344/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21632522/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Oni,%20T.%20et%20al.%20High%20prevalence%20of%20subclinical%20tuberculosis%20in%20HIV-1-infected%20persons%20without%20advanced%20immunodeficiency:%20implications%20for%20TB%20screening.%20Thorax66%20(8),%20669%E2%80%93673%20(2011)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Balcha, T. T. &amp; Jeppsson, A. Outcomes of antiretroviral treatment: a comparison between hospitals and health centers in Ethiopia. <em>J. Int. Assoc. Physicians AIDS Care (Chic)</em>. <strong>9</strong> (5), 318–324 (2010).
</cite> [<a href="https://doi.org/10.1177/1545109710367518" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20923956/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Balcha,%20T.%20T.%20&amp;%20Jeppsson,%20A.%20Outcomes%20of%20antiretroviral%20treatment:%20a%20comparison%20between%20hospitals%20and%20health%20centers%20in%20Ethiopia.%20J.%20Int.%20Assoc.%20Physicians%20AIDS%20Care%20(Chic).%209%20(5),%20318%E2%80%93324%20(2010)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Muñoz-Sellart, M., Cuevas, L., Tumato, M., Merid, Y. &amp; Yassin, M. Factors associated with poor tuberculosis treatment outcome in the Southern region of Ethiopia. <em>Int. J. Tuberc. Lung Dis.</em><strong>14</strong> (8), 973–979 (2010).
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/20626941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mu%C3%B1oz-Sellart,%20M.,%20Cuevas,%20L.,%20Tumato,%20M.,%20Merid,%20Y.%20&amp;%20Yassin,%20M.%20Factors%20associated%20with%20poor%20tuberculosis%20treatment%20outcome%20in%20the%20Southern%20region%20of%20Ethiopia.%20Int.%20J.%20Tuberc.%20Lung%20Dis.14%20(8),%20973%E2%80%93979%20(2010)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Uyei, J., Coetzee, D., Macinko, J. &amp; Guttmacher, S. Integrated delivery of HIV and tuberculosis services in sub-Saharan africa: a systematic review. <em>Lancet. Infect. Dis</em>. <strong>11</strong> (11), 855–867 (2011).
</cite> [<a href="https://doi.org/10.1016/S1473-3099(11)70145-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22035614/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Uyei,%20J.,%20Coetzee,%20D.,%20Macinko,%20J.%20&amp;%20Guttmacher,%20S.%20Integrated%20delivery%20of%20HIV%20and%20tuberculosis%20services%20in%20sub-Saharan%20africa:%20a%20systematic%20review.%20Lancet.%20Infect.%20Dis.%2011%20(11),%20855%E2%80%93867%20(2011)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Fine, J. P. &amp; Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. <em>J. Am. Stat. Assoc.</em><strong>94</strong> (446), 496–509 (1999).</cite> [<a href="https://scholar.google.com/scholar_lookup?Fine,%20J.%20P.%20&amp;%20Gray,%20R.%20J.%20A%20proportional%20hazards%20model%20for%20the%20subdistribution%20of%20a%20competing%20risk.%20J.%20Am.%20Stat.%20Assoc.94%20(446),%20496%E2%80%93509%20(1999)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Gooley, T. A., Leisenring, W., Crowley, J. &amp; Storer, B. E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. <em>Stat. Med.</em><strong>18</strong> (6), 695–706 (1999).
</cite> [<a href="https://doi.org/10.1002/(sici)1097-0258(19990330)18:6&lt;695::aid-sim60&gt;3.0.co;2-o" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10204198/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gooley,%20T.%20A.,%20Leisenring,%20W.,%20Crowley,%20J.%20&amp;%20Storer,%20B.%20E.%20Estimation%20of%20failure%20probabilities%20in%20the%20presence%20of%20competing%20risks:%20new%20representations%20of%20old%20estimators.%20Stat.%20Med.18%20(6),%20695%E2%80%93706%20(1999)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Putter, H., Fiocco, M. &amp; Geskus, R. B. Tutorial in biostatistics: competing risks and multi-state models. <em>Stat. Med.</em><strong>26</strong> (11), 2389–2430 (2007).
</cite> [<a href="https://doi.org/10.1002/sim.2712" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17031868/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Putter,%20H.,%20Fiocco,%20M.%20&amp;%20Geskus,%20R.%20B.%20Tutorial%20in%20biostatistics:%20competing%20risks%20and%20multi-state%20models.%20Stat.%20Med.26%20(11),%202389%E2%80%932430%20(2007)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Bahirdar city health Department. population projection, accounting censuses of 2007 by Ethiopian Statistical Agency (ESA), of Bahirdar city health Department. (2022).</cite>
</li>
<li id="CR40">
<span class="label">40.</span><cite>Ministry of Health Ethiopia. Guidelines for management of Tb, Dr-Tb and leprosy in ethiopia. 6 (2017).</cite>
</li>
<li id="CR41">
<span class="label">41.</span><cite>WHO Guidelines Approved by the Guidelines Review Committee. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: World Health Organization Copyright © World Health Organization (2016).</cite>
</li>
<li id="CR42">
<span class="label">42.</span><cite>Ryan, T. P. <em>Sample Size Determination and Power</em> (Wiley, 2013).</cite>
</li>
<li id="CR43">
<span class="label">43.</span><cite>Epidata manager. <a href="http://www.epidata.dk" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.epidata.dk</a> (2024).</cite>
</li>
<li id="CR44">
<span class="label">44.</span><cite>Stata version 14. <a href="https://www.stata.com/stata14/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.stata.com/stata14/</a></cite>
</li>
<li id="CR45">
<span class="label">45.</span><cite>Cran RStudio.</cite>
</li>
<li id="CR46">
<span class="label">46.</span><cite>Zhang, Z. et al. Overview of model validation for survival regression model with competing risks using melanoma study data. <em>Ann. Transl Med.</em><strong>6</strong> (16), 325 (2018).
</cite> [<a href="https://doi.org/10.21037/atm.2018.07.38" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6186983/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30364028/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang,%20Z.%20et%20al.%20Overview%20of%20model%20validation%20for%20survival%20regression%20model%20with%20competing%20risks%20using%20melanoma%20study%20data.%20Ann.%20Transl%20Med.6%20(16),%20325%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Haller, B., Schmidt, G. &amp; Ulm, K. Applying competing risks regression models: an overview. <em>Lifetime Data Anal.</em><strong>19</strong> (1), 33–58 (2013).
</cite> [<a href="https://doi.org/10.1007/s10985-012-9230-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23010807/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Haller,%20B.,%20Schmidt,%20G.%20&amp;%20Ulm,%20K.%20Applying%20competing%20risks%20regression%20models:%20an%20overview.%20Lifetime%20Data%20Anal.19%20(1),%2033%E2%80%9358%20(2013)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Bakoyannis, G. &amp; Touloumi, G. Practical methods for competing risks data: a review. <em>Stat. Methods Med. Res.</em><strong>21</strong> (3), 257–272 (2012).
</cite> [<a href="https://doi.org/10.1177/0962280210394479" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21216803/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bakoyannis,%20G.%20&amp;%20Touloumi,%20G.%20Practical%20methods%20for%20competing%20risks%20data:%20a%20review.%20Stat.%20Methods%20Med.%20Res.21%20(3),%20257%E2%80%93272%20(2012)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Matsena Zingoni, Z., Chirwa, T., Todd, J. &amp; Musenge, E. Competing risk of mortality on lost to follow-up outcome among patients with HIV on ART: a retrospective cohort study from the Zimbabwe National ART programme. <em>BMJ Open.</em><strong>10</strong> (10), e036136 (2020).
</cite> [<a href="https://doi.org/10.1136/bmjopen-2019-036136" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7539573/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33028546/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Matsena%20Zingoni,%20Z.,%20Chirwa,%20T.,%20Todd,%20J.%20&amp;%20Musenge,%20E.%20Competing%20risk%20of%20mortality%20on%20lost%20to%20follow-up%20outcome%20among%20patients%20with%20HIV%20on%20ART:%20a%20retrospective%20cohort%20study%20from%20the%20Zimbabwe%20National%20ART%20programme.%20BMJ%20Open.10%20(10),%20e036136%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Kiwanuka, J., Mukulu Waila, J., Muhindo Kahungu, M., Kitonsa, J. &amp; Kiwanuka, N. Determinants of lost to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in masaka, Uganda. <em>PLoS One</em>. <strong>15</strong> (4), e0217606 (2020).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0217606" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7138304/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32255796/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kiwanuka,%20J.,%20Mukulu%20Waila,%20J.,%20Muhindo%20Kahungu,%20M.,%20Kitonsa,%20J.%20&amp;%20Kiwanuka,%20N.%20Determinants%20of%20lost%20to%20follow-up%20among%20HIV%20positive%20patients%20receiving%20antiretroviral%20therapy%20in%20a%20test%20and%20treat%20setting:%20A%20retrospective%20cohort%20study%20in%20masaka,%20Uganda.%20PLoS%20One.%2015%20(4),%20e0217606%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Shaweno, T., Getnet, M. &amp; Fikru, C. Does time to lost to follow-up differ among adult tuberculosis patients initiated on tuberculosis treatment and care between general hospital and health centers? A retrospective cohort study. <em>Trop. Med. Health</em>. <strong>48</strong> (1), 1–11 (2020).
</cite> [<a href="https://doi.org/10.1186/s41182-020-00198-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7026974/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32099523/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shaweno,%20T.,%20Getnet,%20M.%20&amp;%20Fikru,%20C.%20Does%20time%20to%20lost%20to%20follow-up%20differ%20among%20adult%20tuberculosis%20patients%20initiated%20on%20tuberculosis%20treatment%20and%20care%20between%20general%20hospital%20and%20health%20centers?%20A%20retrospective%20cohort%20study.%20Trop.%20Med.%20Health.%2048%20(1),%201%E2%80%9311%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Kassa, G. M., Teferra, A. S., Wolde, H. F., Muluneh, A. G. &amp; Merid, M. W. Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at university of Gondar comprehensive specialized hospital, Northwest ethiopia: a retrospective follow-up study. <em>BMC Infect. Dis.</em><strong>19</strong> (1), 817 (2019).
</cite> [<a href="https://doi.org/10.1186/s12879-019-4447-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6751642/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31533661/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kassa,%20G.%20M.,%20Teferra,%20A.%20S.,%20Wolde,%20H.%20F.,%20Muluneh,%20A.%20G.%20&amp;%20Merid,%20M.%20W.%20Incidence%20and%20predictors%20of%20lost%20to%20follow-up%20among%20drug-resistant%20tuberculosis%20patients%20at%20university%20of%20Gondar%20comprehensive%20specialized%20hospital,%20Northwest%20ethiopia:%20a%20retrospective%20follow-up%20study.%20BMC%20Infect.%20Dis.19%20(1),%20817%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Kebede, H. K., Mwanri, L., Ward, P. &amp; Gesesew, H. A. Predictors of lost to follow up from antiretroviral therapy among adults in sub-Saharan africa: a systematic review and meta-analysis. <em>Infect. Dis. Poverty</em>. <strong>10</strong> (1), 33 (2021).
</cite> [<a href="https://doi.org/10.1186/s40249-021-00822-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7981932/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33743815/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kebede,%20H.%20K.,%20Mwanri,%20L.,%20Ward,%20P.%20&amp;%20Gesesew,%20H.%20A.%20Predictors%20of%20lost%20to%20follow%20up%20from%20antiretroviral%20therapy%20among%20adults%20in%20sub-Saharan%20africa:%20a%20systematic%20review%20and%20meta-analysis.%20Infect.%20Dis.%20Poverty.%2010%20(1),%2033%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Megerso, A. et al. Predictors of lost to follow-up in antiretroviral treatment for adult patients in the oromia region, Ethiopia. <em>HIV AIDS (Auckl)</em>. <strong>8</strong>, 83–92 (2016).
</cite> [<a href="https://doi.org/10.2147/HIV.S98137" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4854271/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27175095/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Megerso,%20A.%20et%20al.%20Predictors%20of%20lost%20to%20follow-up%20in%20antiretroviral%20treatment%20for%20adult%20patients%20in%20the%20oromia%20region,%20Ethiopia.%20HIV%20AIDS%20(Auckl).%208,%2083%E2%80%9392%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Birhanu, M. Y. et al. Incidence and predictors of lost to follow-up among HIV-positive adults in Northwest ethiopia: a retrospective cohort study. <em>Trop. Med. Health</em>. <strong>48</strong>, 78 (2020).
</cite> [<a href="https://doi.org/10.1186/s41182-020-00266-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7488994/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32943978/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Birhanu,%20M.%20Y.%20et%20al.%20Incidence%20and%20predictors%20of%20lost%20to%20follow-up%20among%20HIV-positive%20adults%20in%20Northwest%20ethiopia:%20a%20retrospective%20cohort%20study.%20Trop.%20Med.%20Health.%2048,%2078%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Alebel, A., Sibbritt, D., Petrucka, P. &amp; Demant, D. Undernutrition increased the risk of lost to follow-up among adults living with HIV on ART in Northwest ethiopia: a retrospective cohort study. <em>Sci. Rep.</em><strong>12</strong> (1), 22556 (2022).
</cite> [<a href="https://doi.org/10.1038/s41598-022-27077-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9800382/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36581708/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Alebel,%20A.,%20Sibbritt,%20D.,%20Petrucka,%20P.%20&amp;%20Demant,%20D.%20Undernutrition%20increased%20the%20risk%20of%20lost%20to%20follow-up%20among%20adults%20living%20with%20HIV%20on%20ART%20in%20Northwest%20ethiopia:%20a%20retrospective%20cohort%20study.%20Sci.%20Rep.12%20(1),%2022556%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Tesha, E-D., Kishimba, R., Njau, P., Revocutus, B. &amp; Mmbaga, E. Predictors of lost to follow up from antiretroviral therapy among adolescents with HIV/AIDS in Tanzania. <em>PloS One</em>. <strong>17</strong> (7), e0268825 (2022).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0268825" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9299289/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35857796/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tesha,%20E-D.,%20Kishimba,%20R.,%20Njau,%20P.,%20Revocutus,%20B.%20&amp;%20Mmbaga,%20E.%20Predictors%20of%20lost%20to%20follow%20up%20from%20antiretroviral%20therapy%20among%20adolescents%20with%20HIV/AIDS%20in%20Tanzania.%20PloS%20One.%2017%20(7),%20e0268825%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Berheto, T. M., Haile, D. B. &amp; Mohammed, S. Predictors of lost to follow-up in patients living with HIV/AIDS after initiation of antiretroviral therapy. <em>N Am. J. Med. Sci.</em><strong>6</strong> (9), 453–459 (2014).
</cite> [<a href="https://doi.org/10.4103/1947-2714.141636" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4193152/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25317390/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Berheto,%20T.%20M.,%20Haile,%20D.%20B.%20&amp;%20Mohammed,%20S.%20Predictors%20of%20lost%20to%20follow-up%20in%20patients%20living%20with%20HIV/AIDS%20after%20initiation%20of%20antiretroviral%20therapy.%20N%20Am.%20J.%20Med.%20Sci.6%20(9),%20453%E2%80%93459%20(2014)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Fisiha Kassa, S., Zemene Worku, W., Atalell, K. A. &amp; Agegnehu, C. D. Incidence of lost to Follow-Up and its predictors among children with HIV on antiretroviral therapy at the university of Gondar comprehensive specialized referral hospital: A retrospective data analysis. <em>HIV AIDS (Auckl)</em>. <strong>12</strong>, 525–533 (2020).
</cite> [<a href="https://doi.org/10.2147/HIV.S269580" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7547131/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33116915/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fisiha%20Kassa,%20S.,%20Zemene%20Worku,%20W.,%20Atalell,%20K.%20A.%20&amp;%20Agegnehu,%20C.%20D.%20Incidence%20of%20lost%20to%20Follow-Up%20and%20its%20predictors%20among%20children%20with%20HIV%20on%20antiretroviral%20therapy%20at%20the%20university%20of%20Gondar%20comprehensive%20specialized%20referral%20hospital:%20A%20retrospective%20data%20analysis.%20HIV%20AIDS%20(Auckl).%2012,%20525%E2%80%93533%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Fentie, D. T., Kassa, G. M., Tiruneh, S. A. &amp; Muche, A. A. Development and validation of a risk prediction model for lost to follow-up among adults on active antiretroviral therapy in ethiopia: a retrospective follow-up study. <em>BMC Infect. Dis.</em><strong>22</strong> (1), 727 (2022).
</cite> [<a href="https://doi.org/10.1186/s12879-022-07691-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9449961/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36071386/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fentie,%20D.%20T.,%20Kassa,%20G.%20M.,%20Tiruneh,%20S.%20A.%20&amp;%20Muche,%20A.%20A.%20Development%20and%20validation%20of%20a%20risk%20prediction%20model%20for%20lost%20to%20follow-up%20among%20adults%20on%20active%20antiretroviral%20therapy%20in%20ethiopia:%20a%20retrospective%20follow-up%20study.%20BMC%20Infect.%20Dis.22%20(1),%20727%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Hibstie, Y. T. et al. Nearly one in every six HIV-infected children lost from ART follow-up at Debre Markos referral hospital, Northwest ethiopia: A 14-year retrospective follow-up study. <em>PLoS One</em>. <strong>15</strong> (9), e0239013 (2020).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0239013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7491726/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32931502/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hibstie,%20Y.%20T.%20et%20al.%20Nearly%20one%20in%20every%20six%20HIV-infected%20children%20lost%20from%20ART%20follow-up%20at%20Debre%20Markos%20referral%20hospital,%20Northwest%20ethiopia:%20A%2014-year%20retrospective%20follow-up%20study.%20PLoS%20One.%2015%20(9),%20e0239013%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Ogyiri, L. et al. Effect of HIV infection on TB treatment outcomes and time to mortality in two urban hospitals in Ghana-a retrospective cohort study. <em>Pan Afr. Med. J.</em><strong>32</strong> (1). (2019).</cite> [<a href="https://doi.org/10.11604/pamj.2019.32.206.18673" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6620068/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31312318/" class="usa-link">PubMed</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Alebel, A., Demant, D., Petrucka, P. &amp; Sibbritt, D. Effects of undernutrition on opportunistic infections among adults living with HIV on ART in Northwest ethiopia: using inverse-probability weighting. <em>PLoS One</em>. <strong>17</strong> (3), e0264843 (2022).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0264843" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8901070/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35255109/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Alebel,%20A.,%20Demant,%20D.,%20Petrucka,%20P.%20&amp;%20Sibbritt,%20D.%20Effects%20of%20undernutrition%20on%20opportunistic%20infections%20among%20adults%20living%20with%20HIV%20on%20ART%20in%20Northwest%20ethiopia:%20using%20inverse-probability%20weighting.%20PLoS%20One.%2017%20(3),%20e0264843%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Mushy, S. E. et al. Predictors of the observed high prevalence of lost to follow-up in ART-experienced adult PLHIV: a retrospective longitudinal cohort study in the Tanga region, Tanzania. <em>BMC Infect. Dis.</em><strong>23</strong> (1), 92 (2023).
</cite> [<a href="https://doi.org/10.1186/s12879-023-08063-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9926646/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36788523/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mushy,%20S.%20E.%20et%20al.%20Predictors%20of%20the%20observed%20high%20prevalence%20of%20lost%20to%20follow-up%20in%20ART-experienced%20adult%20PLHIV:%20a%20retrospective%20longitudinal%20cohort%20study%20in%20the%20Tanga%20region,%20Tanzania.%20BMC%20Infect.%20Dis.23%20(1),%2092%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<span class="label">65.</span><cite>Núñez, I. et al. Late-onset opportunistic infections while receiving anti-retroviral therapy in Latin america: burden and risk factors. <em>Int. J. Infect. Dis.</em><strong>122</strong>, 469–475 (2022).
</cite> [<a href="https://doi.org/10.1016/j.ijid.2022.06.041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9851270/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35768025/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?N%C3%BA%C3%B1ez,%20I.%20et%20al.%20Late-onset%20opportunistic%20infections%20while%20receiving%20anti-retroviral%20therapy%20in%20Latin%20america:%20burden%20and%20risk%20factors.%20Int.%20J.%20Infect.%20Dis.122,%20469%E2%80%93475%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<span class="label">66.</span><cite>Birhane, M., Mekonnen, S., Dingeta, T. &amp; Teklemariam, Z. Lost to follow-up tuberculosis treatment and associated factors among adults attending at public health facilities in warder district, Somali regional state, Eastern Ethiopia. <em>Front. Public. Health</em>. <strong>11</strong>, 1151077 (2023).
</cite> [<a href="https://doi.org/10.3389/fpubh.2023.1151077" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10208408/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37234759/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Birhane,%20M.,%20Mekonnen,%20S.,%20Dingeta,%20T.%20&amp;%20Teklemariam,%20Z.%20Lost%20to%20follow-up%20tuberculosis%20treatment%20and%20associated%20factors%20among%20adults%20attending%20at%20public%20health%20facilities%20in%20warder%20district,%20Somali%20regional%20state,%20Eastern%20Ethiopia.%20Front.%20Public.%20Health.%2011,%201151077%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<span class="label">67.</span><cite>Walker, I. F. et al. Analysis of lost to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients. <em>Eur. Respir. J.</em><strong>54</strong> (1). (2019).</cite> [<a href="https://doi.org/10.1183/13993003.00353-2018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31073080/" class="usa-link">PubMed</a>]</li>
<li id="CR68">
<span class="label">68.</span><cite>Joung, I. M., van der Meer, J. B. &amp; Mackenbach, J. P. Marital status and health care utilization. <em>Int. J. Epidemiol.</em><strong>24</strong> (3), 569–575 (1995).
</cite> [<a href="https://doi.org/10.1093/ije/24.3.569" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7672898/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Joung,%20I.%20M.,%20van%20der%20Meer,%20J.%20B.%20&amp;%20Mackenbach,%20J.%20P.%20Marital%20status%20and%20health%20care%20utilization.%20Int.%20J.%20Epidemiol.24%20(3),%20569%E2%80%93575%20(1995)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR69">
<span class="label">69.</span><cite>Mengesha, M. M., Gebremichael, M. A., Watumo, D., Hallström, I. K. &amp; Jerene, D. Poor adult tuberculosis treatment outcome and associated factors in Gibe woreda, Southern ethiopia: an institution-based cross-sectional study. <em>PLOS Glob Public. Health</em>. <strong>2</strong> (3), e0000161 (2022).
</cite> [<a href="https://doi.org/10.1371/journal.pgph.0000161" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10021194/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36962264/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mengesha,%20M.%20M.,%20Gebremichael,%20M.%20A.,%20Watumo,%20D.,%20Hallstr%C3%B6m,%20I.%20K.%20&amp;%20Jerene,%20D.%20Poor%20adult%20tuberculosis%20treatment%20outcome%20and%20associated%20factors%20in%20Gibe%20woreda,%20Southern%20ethiopia:%20an%20institution-based%20cross-sectional%20study.%20PLOS%20Glob%20Public.%20Health.%202%20(3),%20e0000161%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR70">
<span class="label">70.</span><cite>Mishra, P. et al. Reasons for lost to follow-up (LTFU) of pulmonary TB (PTB) patients: A qualitative study among saharia, a particularly vulnerable tribal group of Madhya pradesh, India. <em>PLoS One</em>. <strong>16</strong> (12), e0261152 (2021).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0261152" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8699669/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34941885/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mishra,%20P.%20et%20al.%20Reasons%20for%20lost%20to%20follow-up%20(LTFU)%20of%20pulmonary%20TB%20(PTB)%20patients:%20A%20qualitative%20study%20among%20saharia,%20a%20particularly%20vulnerable%20tribal%20group%20of%20Madhya%20pradesh,%20India.%20PLoS%20One.%2016%20(12),%20e0261152%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR71">
<span class="label">71.</span><cite>Soedarsono, S. et al. Determinant factors for lost to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects. <em>BMC Pulm Med.</em><strong>21</strong> (1), 360 (2021).
</cite> [<a href="https://doi.org/10.1186/s12890-021-01735-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8579625/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34758794/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Soedarsono,%20S.%20et%20al.%20Determinant%20factors%20for%20lost%20to%20follow-up%20in%20drug-resistant%20tuberculosis%20patients:%20the%20importance%20of%20psycho-social%20and%20economic%20aspects.%20BMC%20Pulm%20Med.21%20(1),%20360%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR72">
<span class="label">72.</span><cite>Gashu, K. D., Gelaye, K. A. &amp; Tilahun, B. Adherence to TB treatment remains low during continuation phase among adult patients in Northwest Ethiopia. <em>BMC Infect. Dis.</em><strong>21</strong> (1), 1–10 (2021).
</cite> [<a href="https://doi.org/10.1186/s12879-021-06428-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8325825/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34332550/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gashu,%20K.%20D.,%20Gelaye,%20K.%20A.%20&amp;%20Tilahun,%20B.%20Adherence%20to%20TB%20treatment%20remains%20low%20during%20continuation%20phase%20among%20adult%20patients%20in%20Northwest%20Ethiopia.%20BMC%20Infect.%20Dis.21%20(1),%201%E2%80%9310%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR73">
<span class="label">73.</span><cite>Adamashvili, N. et al. Low BMI increases all-cause mortality rates in patients with drug-resistant TB. <em>Int. J. Tuberc Lung Dis.</em><strong>26</strong> (4), 326–333 (2022).
</cite> [<a href="https://doi.org/10.5588/ijtld.21.0450" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9757601/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35351237/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Adamashvili,%20N.%20et%20al.%20Low%20BMI%20increases%20all-cause%20mortality%20rates%20in%20patients%20with%20drug-resistant%20TB.%20Int.%20J.%20Tuberc%20Lung%20Dis.26%20(4),%20326%E2%80%93333%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR74">
<span class="label">74.</span><cite>Aibana, O. et al. Nutritional status and tuberculosis risk in adult and pediatric household contacts. <em>PLoS One</em>. <strong>11</strong> (11), e0166333 (2016).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0166333" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5105945/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27835678/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Aibana,%20O.%20et%20al.%20Nutritional%20status%20and%20tuberculosis%20risk%20in%20adult%20and%20pediatric%20household%20contacts.%20PLoS%20One.%2011%20(11),%20e0166333%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR75">
<span class="label">75.</span><cite>Jiang, Y. et al. Factors associated with lost to follow-up before and after treatment initiation among patients with tuberculosis: A 5-year observation in China. <em>Front. Med. (Lausanne)</em>. <strong>10</strong>, 1136094 (2023).
</cite> [<a href="https://doi.org/10.3389/fmed.2023.1136094" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10167013/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37181365/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jiang,%20Y.%20et%20al.%20Factors%20associated%20with%20lost%20to%20follow-up%20before%20and%20after%20treatment%20initiation%20among%20patients%20with%20tuberculosis:%20A%205-year%20observation%20in%20China.%20Front.%20Med.%20(Lausanne).%2010,%201136094%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR76">
<span class="label">76.</span><cite>Lai, H. H., Lai, Y. J. &amp; Yen, Y. F. Association of body mass index with timing of death during tuberculosis treatment. <em>PLoS One</em>. <strong>12</strong> (1), e0170104 (2017).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0170104" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5234803/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28085951/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lai,%20H.%20H.,%20Lai,%20Y.%20J.%20&amp;%20Yen,%20Y.%20F.%20Association%20of%20body%20mass%20index%20with%20timing%20of%20death%20during%20tuberculosis%20treatment.%20PLoS%20One.%2012%20(1),%20e0170104%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR77">
<span class="label">77.</span><cite>Wondimu, W., Dube, L. &amp; Kabeta, T. Factors affecting survival rates among adult TB/HIV Co-Infected patients in Mizan Tepi university teaching hospital, South West Ethiopia. <em>HIV AIDS (Auckl)</em>. <strong>12</strong>, 157–164 (2020).
</cite> [<a href="https://doi.org/10.2147/HIV.S242756" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7185339/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32368156/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wondimu,%20W.,%20Dube,%20L.%20&amp;%20Kabeta,%20T.%20Factors%20affecting%20survival%20rates%20among%20adult%20TB/HIV%20Co-Infected%20patients%20in%20Mizan%20Tepi%20university%20teaching%20hospital,%20South%20West%20Ethiopia.%20HIV%20AIDS%20(Auckl).%2012,%20157%E2%80%93164%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR78">
<span class="label">78.</span><cite>Michael, O. S., Sogaolu, O. M., Fehintola, F. A., Ige, O. M. &amp; Falade, C. O. Adverse events to first line anti-tuberculosis drugs in patients co-infected with HIV and tuberculosis. <em>Ann. IB. Postgrad. Med.</em><strong>14</strong> (1), 21–29 (2016).
</cite> [<a href="/articles/PMC5049598/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27721682/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Michael,%20O.%20S.,%20Sogaolu,%20O.%20M.,%20Fehintola,%20F.%20A.,%20Ige,%20O.%20M.%20&amp;%20Falade,%20C.%20O.%20Adverse%20events%20to%20first%20line%20anti-tuberculosis%20drugs%20in%20patients%20co-infected%20with%20HIV%20and%20tuberculosis.%20Ann.%20IB.%20Postgrad.%20Med.14%20(1),%2021%E2%80%9329%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR79">
<span class="label">79.</span><cite>Sant Anna, F. M. et al. Impact of adverse drug reactions on the outcomes of tuberculosis treatment. <em>PLoS One</em>. <strong>18</strong> (2), e0269765 (2023).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0269765" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9904486/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36749743/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sant%20Anna,%20F.%20M.%20et%20al.%20Impact%20of%20adverse%20drug%20reactions%20on%20the%20outcomes%20of%20tuberculosis%20treatment.%20PLoS%20One.%2018%20(2),%20e0269765%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR80">
<span class="label">80.</span><cite>Manosuthi, W., Wiboonchutikul, S. &amp; Sungkanuparph, S. Integrated therapy for HIV and tuberculosis. <em>AIDS Res. Ther.</em><strong>13</strong>, 22 (2016).
</cite> [<a href="https://doi.org/10.1186/s12981-016-0106-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4866405/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27182275/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Manosuthi,%20W.,%20Wiboonchutikul,%20S.%20&amp;%20Sungkanuparph,%20S.%20Integrated%20therapy%20for%20HIV%20and%20tuberculosis.%20AIDS%20Res.%20Ther.13,%2022%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>All the data are available within the manuscript. If additional datasets are required, they can be obtained from the corresponding author upon a reasonable request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Scientific Reports are provided here courtesy of <strong>Nature Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1038/s41598-025-15985-8"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/41598_2025_Article_15985.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.0 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12365281/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12365281/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365281%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365281/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12365281/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12365281/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40830417/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12365281/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40830417/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12365281/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12365281/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="BptZZrTAFMXDdRWn1yJHHbe8LCZyJdmnZO50mikfoRmvF1KipxFrXrPOk1COW6ti">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
